Enhanced emotional memory retrieval by chemogenetic activation of locus coeruleus norepinephrine neurons

Ryoji Fukabori[1†], Yoshio Iguchi[1†], Shigeki Kato[1], Kazumi Takahashi[2], Satoshi Eifuku[2], Shingo Tsuji[3], Akihiro Hazama[3], Motokazu Uchigashima[4,††], Masahiko Watanabe[4], Hiroshi Mizuma[5], Yilong Cui[6], Hirotaka Onoe[7], Keigo Hikishima[8], Yasunobu Yasoshima[9], Makoto Osanai[10], Ryo Inagaki[11], Kohji Fukunaga[11], Takuma Nishijo[12], Toshihiko Momiyama[12], Richard Benton[13], Kazuto Kobayashi[1*]

[1] Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan; [2]Department of Systems Neuroscience, Fukushima Medical University School of Medicine, Fukushima Japan; [3]Department of Cellular and Integrated Physiology, Fukushima Medical University School of Medicine, Japan; [4]Department of Anatomy, Faculty of Medicine, Hokkaido University, Japan; [5]Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan; [6]Laboratory for Biofunction Dynamics Imaging, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan

[7]Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto,

Japan; [8]Animal Resources Section, Okinawa Institute of Science and Technology

Graduate University, Okinawa, Japan; [9]Division of Behavioral Physiology, Department

of Behavioral Sciences, Graduate School of Human Science, Osaka University, Suita,

Japan; [10]Department of Medical Physics and Engineering, Division of Health Sciences,

Osaka University Graduate School of Medicine, Suita, Japan; [11]Department of

Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai,

Japan; [12]Department of Pharmacology, Jikei University School of Medicine, Tokyo,

Japan; [13]Center for Integrative Genomics, Faculty of Biology and Medicine, University

of Lausanne, Lausanne, Switzerland

[*]**For correspondence:** kazuto@fmu.ac.jp (KK)

[†]These authors contributed equally to this work

[††]Present address: Motokazu Uchigashima, Department of Cellular Neuropathology,

Brain research Institute, Niigata University, Niigata, Japan

Competing interest: The authors declare no competing interests exist.

Abstract The ability to retrieve memory store in response to the environment is

essential for animal behavioral adaptation. Norepinephrine (NE)-containing neurons in

the brain play a key role in the modulation of synaptic plasticity underlying various

processes of memory formation. However, the role of the central NE system in memory

retrieval remains unclear. In this study we developed a neural chemogenetic activation

strategy using insect olfactory Ionotropic Receptors (IRs), which we used it for selective

stimulation of NE neurons in the locus coeruleus (LC) in transgenic mice.

Ligand-induced activation of LC NE neurons resulted in enhancement of the retrieval

process of conditioned taste aversion, which was mediated through at least partly

adrenergic receptors in the amygdala. Pharmacological blockade of LC activity

confirmed the facilitative role of these neurons in memory retrieval. Our findings

indicate that the LC-amygdalar pathway is required and sufficient for enhancing the

recall of taste associative memory.

1   Introduction

The ability to retrieve necessary information associated with environmental stimuli and

context is indispensable for animal behavioral adaptation. Disturbances in this

information retrieval process, especially in humans, result in degradation of not only

quality of life but also the sense of personal identity (*Klein and Nichols, 2012*).

Impairments specific to the retrieval process have been reported in some amnesiac

patients, who exhibit the inability to explicitly recall test stimuli despite their spared

implicit memory of the same stimuli, which can be retrieved with prompts or partial

information (*Warrington and Weiskrantz, 1970*). By contrast, recurrent involuntary

memory retrieval after traumatic events is one of the major symptoms of post-traumatic

stress disorder (*American Psychiatric Association, 2013*). A number of clinical and

preclinical studies have suggested that multiple neurotransmitter/modulator systems are

implicated in the retrieval process (*Kopelman, 1992*), but the detailed neural mechanism

of this process is not well understood.

Norepinephrine (NE)-containing neurons in the brain are divided into discrete cell

groups in the pons and medulla, projecting to a diverse array of brain regions (*Chandler*

et al., 2014; Robertson et al., 2013). NE plays a key role in the modulation of

long-lasting synaptic potentiation and strengthening in the hippocampus (*Gelinas and*

Nguyen, 2005; Huang and Kandel, 1996; O'Dell et al., 2010) and amygdala (*Huang et*

al., 2000; Huang and Kandel, 2007; Johansen et al., 2014). Indeed, a number of

behavioral studies demonstrate that the central NE system contributes to associative

aversive memory processes, including acquisition (*Bahar et al., 2003; Bush et al.,*

2010; Ferry et al., 2015), consolidation (*Guzmán-Ramos et al., 2012; LaLumiere et al.,*

2013), and reconsolidation (*Kobayashi et al., 2000; Villain et al., 2016; Zhou et al.,*

2015).

By contrast, studies of the NE system in the retrieval process with different

behavioral tasks have produced controversial results. Electrical stimulation of the locus

coeruleus (LC), the major NE cell group in the brain (*Chandler et al., 2014; Robertson*

et al., 2013), enhances performance in a complex maze task during a retention test,

which is blocked by administration of a β-adrenergic receptor antagonist (*Devauges and*

Sara, 1991; Sara and Devauges, 1988). A genetic study with knockout mice for

dopamine β-hydroxylase showed that NE is involved in the retrieval of a particular type

of contextual and spatial memory dependent on the hippocampus (*Murchison et al., 2004*). However, application of a β-adrenergic receptor antagonist into the amygdala does not influence the retrieval of conditioned flavour aversion requiring amygdalar function (*Miranda et al., 2007*). Therefore, the exact role of the central NE system in memory retrieval still remains unclear.

In this study we address the role of NE neurons, focusing on the LC in the retrieval process of conditioned taste aversion. We developed a novel chemogenetic approach to activate specific neuronal types that employs olfactory Ionotropic Receptors (IRs) from *Drosophila melanogaster* (*Abuin et al., 2011; Grosjean et al., 2011*). This approach, which we have named INTENS (insect ionotropic receptor-mediated neuronal stimulation), enables efficient and sustained stimulation of the target neurons. The INTENS technology achieved the activation of LC NE neurons expressing IRs in response to exogenous ligands, and the resultant stimulation of NE release enhanced retrieval of conditioned memory for taste. This role of the LC NE neurons in memory retrieval was mediated at least in part through α_1- and β-adrenergic receptors in the amygdala. Pharmacological experiments that inhibit LC NE activity

confirmed the facilitative role of these neurons in memory retrieval through the

LC-amygdalar pathway via adrenergic receptor subtypes.

Results

Insect IR-mediated stimulation of LC NE neurons

IRs constitute a family of sensory ligand-gated ion channels distantly related to

ionotropic glutamate receptors and mediate environmental chemical detection in

Drosophila melanogaster and other insects (*Benton et al., 2009; Rytz et al., 2013*). The

heteromeric complex composed of IR84a and IR8a subunits confers excitatory cellular

responsiveness to odorants such as phenylacetaldehyde (PhAl) and phenylacetic acid

(PhAc) (*Abuin et al., 2011; Grosjean et al., 2011*). We used this odorant-specific

reaction of the IR84a/IR8a complex for the INTENS technology (*Figure 1A*).

IR84a/IR8a genes are expressed under the control of a cell type-specific gene promoter,

and the target neurons are stimulated with exogenous ligands (PhAl/PhAc). To express

the receptors in NE neurons, we generated transgenic (Tg) mice carrying the genes in

which IR84a fused to enhanced green fluorescent protein (EGFP) was connected to

IR8a via a 2A peptide, downstream of the tyrosine hydroxylase (TH) gene promoter

(*Sawamoto et al., 2001*) (*Figure 1B*). Immunostaining for GFP indicated the transgene

expression in LC neurons in the TH-EGFP-IR84a/IR8a mouse line, whereas there was

no expression in the non-Tg littermates (*Figure 1C, Figure 1—figure supplement 1A*

for expression patterns in other catecholamine-containing cell groups). In the Tg mice,

EGFP-IR84a expression was colocalized with TH immunoreactivity, and IR8a

reactivity was colocalized with signals for NE transporter (NET) (*Figure 1D*). Double

immunostaining for GFP and TH showed that almost all LC neurons express these

receptors ($93.6 \pm 0.02\%$ TH^+/GFP^+ cells/total TH^+ cells, n = 4). *In situ* hybridization

with antisense probes also confirmed both IR84a and IR8a gene expression in the

Tg-mouse LC (*Figure 1—figure supplement 1B*).

To examine cellular responsiveness of LC NE neurons expressing IR84a/IR8a, we

performed a whole-cell current-clamp recording of slice preparations (*Figure 1E*). NE

cells in the LC were identified by a low firing frequency (< 7 Hz) with large

after-hyperpolarization, as observed in previous studies (*van den Pol et al., 2002;*

Zhang et al., 2010). In *Drosophila*, robust activation of IR84a/IR8a-expressing cells

was induced by treatment with 0.1% (8.3 mM) PhAl (*Abuin et al., 2011*). We used 0.1%

solution of the ligands for bath application in slices. The PhAl application depolarized

the membrane and increased the firing frequency of NE neurons in the LC of Tg mice

(*Figure 1F*), whereas it had little or no effect on the membrane potential of non-Tg LC

neurons (*Figure 1G*). The firing frequency of neurons in the Tg mice was significantly

increased from 0.18 ± 0.05 Hz to 2.34 ± 0.49 Hz by PhAl (*Figure 1K*, n = 11, paired

two-tailed t-test, $t_{10} = 4.462$, p = 0.0012). The frequency was similar before and after

PhAl application (0.33 ± 0.06 and 0.41 ± 0.09, respectively) in non-Tg mice (*Figure 1K*,

n = 4, paired two-tailed t-test, $t_3 = 1.999$, p = 0.1395). The amplitude of PhAl-induced

depolarization (7.57 ± 0.72 mV) was significantly higher than the non-Tg value ($0.89 \pm$

0.10 mV) (*Figure 1L*, unpaired two-tailed t-test, $t_{14} = 5.201$, p < 0.0005).

Like the PhAl response, bath application of 0.1% (7.3 mM) PhAc depolarized the

membrane of LC NE neurons in Tg mice, increasing the firing frequency (*Figure 1H*).

In 5 out of 17 neurons examined, the firing stopped after depolarization had reached its

steady state even in the presence of PhAc (*Figure 1I*), indicating the occurrence of

depolarization block in these neurons. In non-Tg mice, PhAc had little or no effect on

the firing frequency or membrane potential of LC neurons (*Figure 1J*). Excluding the

neurons showing depolarization block, the firing frequency in the Tg was significantly

elevated from 3.04 ± 1.04 Hz to 5.47 ± 1.38 Hz by PhAc (*Figure 1M*, n = 12, paired

two-tailed t-test, $t_{11} = 2.667$, p = 0.0219). The frequency was similar before and after

PhAc application (2.63 ± 1.48 Hz and 2.35 ± 1.25 Hz, respectively) in non-Tg mice

(*Figure 1M*, n = 4, paired two-tailed t-test, $t_3 = 1.011$, p = 0.3864). The amplitude of

PhAc-induced depolarization was 9.25 ± 0.69 mV including the neurons in which

depolarization block was observed, and significantly greater compared to the non-Tg

value (0.34 ± 0.08 mV) (*Figure 1N*, Levene's test, $F_{(1, 20)} = 5.060$, p = 0.0365, unpaired

two-tailed t-test with Welch's method, $t_{16.42} = 12.92$, p < 0.0001). The baseline firing of

LC neurons in the preparations used for PhAc application appeared to show higher

frequency than in the case of PhAl, but the average of these values ranged within ~7 Hz

as the definition of LC NE neurons, and the values were also indistinguishable between

the Tg and non-Tg groups in each preparation. The data obtained from the *in vitro*

electrophysiology indicated that application of exogenous ligands induced excitatory

cellular responsiveness of LC NE neurons expressing IR84a/IR8a. The INTENS

technique enables us to stimulate the firing activity of specific neuronal types by

treating with these ligands.

To confirm this ligand-specific reaction of the receptors in mammalian cultured

cells, we generated a lentiviral vector to express IR84a/IR8a complex. HEK293T cells

were transduced with the lentiviral vector, and the expression of the two receptors was

detected by immunohistochemistry (*Figure 1—figure supplement 1C*). A whole-cell

voltage-clamp experiment indicated that PhAc application induced a dose-dependent

increase in the inward currents in the cells (*Figure 1—figure supplement 1D and E*). In

addition to the slice electrophysiology, the data support the suggestion that IR84a/IR8a

complex forms a functional receptor in response to exogenous ligands in the

mammalian system.

***In Vivo* activation of LC neurons stimulates NE release**

To explore whether the INTENS technique can trigger *in vivo* noradrenergic activation,

we performed an extracellular single-unit recording of LC NE neurons (*Figure 2A*). NE

cells in the LC were identified based on firing frequency and waveform as described

(*Takahashi et al., 2010*). For the *in vivo* electrophysiology, we used the concentration

of 1% of PhAc for pneumatic injection. The injection of PhAc into the LC induced a

robust increase of firing activity in Tg mice, whereas LC neurons in non-Tg controls

were insensitive to PhAc injection (*Figure 2B* for typical firing patterns). The firing

rate of Tg neurons was significantly increased from 1.13 ± 0.24 Hz to 3.73 ± 0.31 Hz

after PhAc injection (*Figure 2C*, n = 6, paired two-tailed t-test, $t_5 = 11.53$, $p < 0.0001$),

whereas the rate did not alter before and after PhAc injection (1.20 ± 0.21 Hz and 1.22

± 0.15 Hz, respectively) in non-Tg mice (*Figure 2C*, n = 4, paired two-tailed t-test, $t_4 =$

0.300, $p = 0.7788$). When the effect of PhAc on the discharge of non-NE neurons

around the LC was tested, these neurons were categorized into two groups showing low

and high frequency of firing activity. The firing rate in each group was unaffected by

PhAc injection (*Figure 2D*, n = 5 or 7, paired two-tailed t-test, $t_4 = 0.460$, $p = 0.6696$

for low frequency, $t_6 = 0.880$, $p = 0.4125$ for high frequency). These data indicated that

ligand treatment indeed activates the *in vivo* firing of LC NE neurons harbouring

IR84a/IR8a.

    To further assess ligand-induced noradrenergic activation, we measured NE

release in the brain region innervated by the LC using a microdialysis procedure,

dialysis samples were collected from the anterior cingulate cortex (ACC) (*Figure 2E*).

When we first tested 0.1% PhAc for LC microinjection in this microdialysis, the

extracellular NE level did not show a significant increase in the ACC (*Figure 2—figure*

supplement 1A and B). We therefore used higher concentrations of PhAc (0.4% and

0.6%) for the microinjection. There was no significant difference in average tonic NE

concentration (pg/sample) between the two kinds of mice during baseline fractions

before the microinjection: Tg, 0.24 ± 0.07 (n = 18), non-Tg, 0.30 ± 0.08 (n = 10)

(unpaired two-tailed t-test, $t_{26} = 0.518$, p = 0.6091). Injection of both 0.4% and 0.6%

PhAc into the LC caused a rapid and transient increase in the extracellular NE level in

the Tg mice (*Figure 2F*, n = 6 for each group, two-way mixed-design ANOVA, drug

effect: $F_{(2, 15)} = 9.607$, p = 0.0021, fraction effect: $F_{(6, 90)} = 6.446$, p < 0.0001,

interaction: $F_{(12, 90)} = 3.269$, p = 0.0006). The NE level at the 30-min fraction was

significantly increased to approximately 157% and 233% of the baseline level for 0.4%

and 0.6% PhAc injection, respectively ($t_{105} = 2.215$, p = 0.0289 for 0.4% vs PBS, p <

0.0001 for 0.6% vs PBS), and the effect size was dose dependent (p = 0.0059 for 0.6%

vs 0.4%). Injection of 0.6% PhAc induced a subsequent elevation in the NE level at a

timing delayed after the first peak for 90-min (t_{105} = 3.892, p = 0.0005) and 120-min

fractions (t_{105} = 4.223, p < 0.0005) vs PBS, suggesting the presence of other complex

mechanisms for IR-dependent neuronal activation in addition to the influx of

monovalent cations. In non-Tg animals, 0.6% PhAc injection did not generate any

significant changes in NE release (*Figure 2F*, n = 5 for each group, two-way

mixed-design ANOVA, drug effect: $F_{(1, 8)}$ = 1.326, p = 0.2828, fraction effect: $F_{(6, 48)}$ =

0.403, p = 0.8735, interaction: $F_{(6, 48)}$ = 0.297, p = 0.9356). Similarly, the PhAc-induced

LC activation also increased the release of NE in the amygdala of the Tg mice (*Figure

2—figure supplement 1C-E*). One week after the microdialysis experiments, the

animals were subjected to histological analysis to validate non-specific toxicity of PhAc

treatment to the mouse brain. Immunostaining for TH/NET and cresyl violet staining

did not indicate any non-specific damage to LC neurons treated with 0.4%/0.6% PhAc

(*Figure 2—figure supplement 1F-H*). Staining of cell death markers also confirmed

the lack of cytotoxicity of PhAc treatment (*Figure 2—figure supplement 1I*). These

data confirmed LC noradrenergic activation by the INTENS strategy, which resulted in

the stimulated NE release in the nerve terminal regions innervated by the LC.

Additionally, we tested whether exogenous ligands could stimulate specific

neuronal types expressing the receptors in the brain through systemic administration.

Since methyl ester derivatives are known to possess high permeability through the

blood-brain barrier (*Shukuri et al., 2011; Suzuki et al., 2004; Takashima-Hirano et*

al., 2010), methyl phenylacetic acid (MPhAc) was used as a ligand precursor, which is

converted to PhAc by esterase activity in the brain (*Figure 2G*). MPhAc solution (20

mg/kg) or vehicle was intravenously administered in the Tg mice and then used for *in*

vivo electrophysiology. The firing rate of LC neurons was significantly elevated from

0.74 ± 0.18 Hz to 1.59 ± 0.27 Hz after MPhAc administration (*Figure 2H*, n = 5-7,

unpaired two-tailed t-test, $t_{10} = 2.413$, p = 0.0365), whereas change in the rate before

and after vehicle administration was not significant (0.73 ± 0.13 Hz and 1.08 ± 0.17 Hz,

respectively) (*Figure 2H*, n = 6-7, unpaired two-tailed t-test, $t_{11} = 1.614$, p = 0.1347).

Next, microdialysis samples collected from the ACC were analysed for NE release.

Systemic administration of MPhAc resulted in a marked increase in the extracellular NE

level in the Tg mice (*Figure 2I*, n = 4 for each group, two-way ANOVA, group effect:

$F_{(2, 9)} = 24.06$, $p < 0.0001$, fraction effect: $F_{(6, 54)} = 6.807$, $p < 0.0001$, interaction $F_{(12, 54)}$

$= 5.584$, $p < 0.0001$), and NE level at each fraction was significantly higher than the

level of vehicle-administered Tg mice (30-120 min, $ts_{63} > 3.385$, $ps < 0.05$) or

MPhAc-administered non-Tg (60-120 min, $ts_{63} > 2.894$, $ps < 0.05$). These data suggest

that systemic administration of a ligand precursor, through translocation across the

blood-brain barrier, efficiently stimulates NE activity in the Tg animals.

Ligand-induced LC activation results in enhanced memory retrieval

To address the role of LC NE neurons in memory retrieval, we conducted selective

activation of these neurons using INTENS and investigated its impact on the retrieval

process of conditioned taste aversion, in which animals learn an association between a

taste stimulus and a visceral malaise-inducing stimulus (*Bermúdez-Rattoni, 2004;*

Yamamoto et al., 1994). We used a taste reactivity test, which is a sensitive marker of

taste aversion (*Inui et al.,2013; Yasoshima and Shimura, 2017*) (*Figure 3A* for the

behavioral procedure and *Figure 3B* for the experimental apparatus). In this paradigm,

taste aversion memory was formed by repeated conditioning, in which the voluntary

consumption of 0.5 M sucrose as a conditioned stimulus (CS) was followed by

intraperitoneal 0.15 M lithium chloride (LiCl) injection (2% of body weight) as an

unconditioned stimulus (US). After the habituation period, animals received bilateral

injections of PBS or PhAc solution into the LC 20 min prior to the intraoral infusion of

the CS fluid. We used 0.4% and 0.6% PhAc, which induced a significant increase in NE

level in the microdialysis experiment. Animal behavior was recorded, and the latency to

express the rejection responses (gaping, chin rubbing, forelimb flailing, paw wiping,

and CS dropping) was measured. The latency to express the responses in the Tg mice

differed significantly among the treatments into the LC (*Figure 3C*, n = 8-9 for each

group, $F_{(2, 23)}$ = 7.214, p = 0.0037), and the values for the 0.4% PhAc (95.25 ± 14.25 s, p

= 0.0189) and 0.6% PhAc (79.22 ± 12.39 s, p = 0.0050) injections showed a significant

shortening compared to the PBS injection (196.78 ± 35.91 s), whereas the latency for

the PhAc injection into the non-Tg LC at the same concentrations (187.88 ± 42.62 s for

0.4% PhAc and 180.25 ± 35.88 s for 0.6% PhAc) demonstrated no significant

differences compared to the PBS injection (189.09 ± 36.58 s) (*Figure 3C*: n = 8-11 for

each group, $F_{(2, 24)}$ = 0.0149, p = 0.9853). These results suggest that PhAc-induced

activation of LC NE neurons enhances the retrieval process of conditioned taste

aversion.

During the recording of animal behavior, we counted the number of rejection

responses. The time course of the responses during a the test period indicated that the

responses in the Tg mice were generated at earlier phases after 0.4% or 0.6% PhAc

injection compared to the PBS injection, although the total number of aversive

responses during the test period was similar in the three treatment groups (*Figure*

3—figure supplement 1). The data suggest no apparent change in memory storage by

the LC stimulation in our experimental condition. Therefore, in the following analyses

the effect of ligand-induced LC activation on memory retrieval was evaluated by

measuring the latency for rejection behaviors.

The reduction in the latency to express the rejection responses may be attributable

to increased sensitivity to taste stimulus. To test this possibility, we examined whether

the activation of LC NE neurons changes the sensitivity of taste by measuring the

consumption of 0.5 M sucrose presented to unconditioned animals. Mice received the

bilateral injection of PBS or PhAc solution (0.6%) into the LC, and the fluid intake of

0.5 M sucrose was measured. In both Tg and non-Tg animals, the intake was not

significantly different between the PBS- or PhAc-injected groups (*Figure 3D*, n = 4-7

for each group, unpaired two-tailed t-test, $t_8 = 0.061$, p = 0.9531 for Tg mice, $t_{11} =$

0.595, p = 0.5636 for non-Tg mice). To further confirm that the activated LC NE

neurons does not affect sensitivity to the taste stimulus, we checked the hedonic

responses of unconditioned mice to 0.5 M sucrose using the taste reactivity test. Tg

mice were given bilateral injections of PBS or 0.6% PhAc into their LC 20 min prior to

the intraoral infusion of 0.5 M sucrose. Animal behavior was recorded, and the latency

to express the hedonic responses (tongue protrusion and lateral tongue protrusion) was

measured. The latency for these responses did not significantly differ between the PBS-

and PhAc-injected groups (28.83 ± 8.03 and 33.83 ± 8.33 s, respectively, *Figure 3E*, n

= 6 for each group, unpaired two-tailed t-test, $t_{10} = 0.432$, p = 0.6749), excluding the

possibility that the reduction in the latency by LC stimulation simply results from

increased sensitivity to the taste stimulus.

It is also possible that the activation of LC NE neurons may promote a state of

general arousal, resulting in enhancement of unconditioned responses to aversive events

irrespective of memory retrieval. To test this possibility, we examined whether the

activation of LC NE neurons alters the rejection responses of mice to an unconditioned

bitter tastant, quinine, using the reactivity test. Tg mice received bilateral injection of

PBS or 0.6% PhAc into the LC 20 min prior to the intraoral infusion of the 200 μM

quinine solution, which induced substantial aversive responses. The latency for

rejection responses was not significantly different between the Tg and non-Tg groups

(57.75 ± 13.26 s and 54.25 ± 11.34 s, respectively, *Figure 3F*, n = 8 for each group,

unpaired two-tailed t-test, $t_{14} = 0.201$, p = 0.8439). These data indicate that the

activation of LC NE neurons does not enhance unconditioned response to aversive

stimulus and exclude the possibility that the reduced latency by LC stimulation simply

results from increased arousal level and potentiated general emotional responses to an

innate gustatory stimulus.

In addition, locomotor activity of the treated mice was monitored in the open field

apparatus. Mice were habituated to the environment for 60 min and injected bilaterally

with PBS and then with PhAc solution (0.6%) into the LC. Locomotor activity (60 min)

was not significantly different among the Tg and non-Tg groups after PBS or PhAc

injection (*Figure 3G*, n = 7 for each group, two-way ANOVA, group effect: $F_{(1, 12)}$ =

0.512, p = 0.4878, time-block effect: $F_{(17, 204)}$ = 60.47, p < 0.0001, and interaction: $F_{(17, 204)}$

$_{204)}$ = 0.480, p = 0.9599). Locomotion of Tg mice after PhAc injection was apparently

normal, suggesting that the reduced latency of taste reactivity by LC stimulation cannot

be explained by changes in general motor behavior by PhAc injection.

Based on these behavioral evidences, we conclude that the activation of LC NE

neurons in response to the exogenous ligand promotes the retrieval process of aversive

memory for events acquired through conditioning with a specific taste stimulus.

Neural pathway mediating enhanced memory retrieval through LC activation

The formation of conditioned taste aversion requires the function of the amygdala

(*Bermúdez-Rattoni, 2004; Yamamoto et al., 1994*), which receives innervation from

LC NE neurons (*Chandler et al., 2014; Robertson et al., 2013*). To determine whether

the LC-amygdalar noradrenergic pathway is involved in the enhancement of memory

retrieval, we performed pharmacological blockade experiments for taste reactivity using

prazosin (PRAZ) and propranolol (PROP) as α_1- and β-adrenergic receptor antagonists,

respectively. First, to check doses of adrenergic receptor antagonists infused into the

amygdala that do not affect taste reactivity in wild-type mice, we tested the effect of

bilateral intra-amygdalar treatment with PRAZ (0.1 or 0.5 µg/site) or PROP (0.4 or 2.0

µg/site) on the wild-type reactivity. The CS fluid was then intraorally infused, and the

latency for reaction response initiation was measured. The latency to reject the CS

differed significantly among the groups (*Figure 4A*, n = 7-10, one-way ANOVA, $F_{(4, 36)}$

= 4.830, p = 0.0032), and the values for the groups treated with higher doses of PRAZ

(340.75 ± 38.63 s) and PROP (334.57 ± 34.66 s) were significantly lengthened

compared to the PBS-treated controls (156.1 ± 37.42 s, p = 0.0138 for PRAZ, p =

0.0252 for PROP). In contrast, the latency in the groups treated with lower doses of

PRAZ (190.75 ± 39.12 s) or PROP (187.75 ± 47.88 s) did not show any significant

differences compared to PBS treatment (p = 0.9681 for PRAZ, p = 0.9770 for PROP).

Thus, intra-amygdala infusion of lower doses of PRAZ and PROP does not influence

the latency of taste reactivity in wild-type animals, whereas the data obtained from the

use of higher doses of the antagonists show the necessity of the amygdala for the

retrieval process of conditioned taste aversion.

Next, we tested whether enhanced memory retrieval by LC stimulation can be

blocked by the intra-amygdala treatment with lower doses of adrenergic receptor

antagonists that do not affect taste reactivity in wild-type animals. The Tg and non-Tg

mice were given the bilateral intra-amygdala treatment of PRAZ (0.1 µg/site) or PROP

(0.4 µg/site), which was then followed by the injection of PhAc solution (0.6%) into the

LC. The latency to reject the CS in the Tg mice significantly differed among the three

groups (*Figure 4B*, n = 8-9 for each group, one-way ANOVA, $F_{(2, 23)} = 5.860$, p =

0.0088), and the values for the PRAZ- and PROP-treated groups (176.00 ± 26.81 s and

199.11 ± 25.96 s, respectively) were significantly elevated compared to the PBS-treated

controls (83.75 ± 19.63 s, p=0.0402 for PRAZ, p=0.0092 for PROP). By contrast, the

latency in the non-Tg mice for the treatment of PRAZ (196.14 ± 47.75 s) or PROP

(162.57 ± 37.33 s) displayed no significant differences compared to PBS treatment

(186.43 ± 20.10 s) (*Figure 4B*: n = 7 for each group, $F_{(2, 18)} = 0.220$, p = 0.8050).

Therefore, the enhanced retrieval of conditioned taste memory by LC noradrenergic

activation is blocked by either α_1- or β-adrenergic antagonist treated into the amygdala,

suggesting that the retrieval process is mediated, at least in part, through α_1- and

β-adrenergic receptor signalling via the LC-amygdalar pathway.

Impact of pharmacological inhibition of LC neurons on memory retrieval

To ascertain the enhancing effect of LC noradrenergic activation on memory retrieval,

we tested whether the inhibition of LC NE activity would suppress the taste memory

retrieval process. Wild-type mice were given an infusion of clonidine (CLO), which is

an α_2 adrenergic receptor agonist that inhibits LC activity (*Aghajanian and*

VanderMalen, 1982; Washburn and Moises, 1989), into the bilateral LC and subjected

to the reactivity test. Latency to reject the CS differed significantly according to the

treatments (*Figure 5A*, n = 7-8 for each group, one-way ANOVA, $F_{(2, 20)} = 17.19$, p <

0.0001), the value for the lower (10 ng/site) or higher (25 ng/site) doses of CLO (380.86

± 20.13 s and 292.50 ± 29.23 s, respectively) exhibited a significant lengthening

compared to PBS injection (165.25 ± 26.14 s, p < 0.0001 for the lower dose, p = 0.0055

for the higher dose). The inhibition of LC NE activity actually resulted in the

suppression of the retrieval of taste memory, which is consistent with the facilitative

role of these neurons in the memory retrieval process.

To further validate adrenergic receptor function in the amygdala during

memory retrieval, we investigated whether the activation of adrenergic receptor

subtypes in the amygdala can restore suppressed memory retrieval by inhibition of LC

activity. Wild-type mice received bilateral intra-LC infusion of CLO (10 ng/site), and

then bilateral intra-amygdalar treatment of α_1-adrenergic receptor agonist methoxamine

(MET) or β-adrenergic receptor agonist isoproterenol (ISO) for taste reactivity. The

latency to reject CS in the CLO-injected mice differed significantly according to

treatment into the amygdala (*Figure 5B*, n = 7-8 for each group, one-way ANOVA, $F_{(2, 20)}$

$= 20.83$, $p < 0.0001$), and the values in MET and ISO treatment (169.00 ± 31.06 s and

150.00 ± 21.45 s, respectively) showed a significant shortening compared to PBS

treatment (462.00 ± 56.65 s, $p < 0.0001$ for the MET and ISO treated groups). The data

indicate that α_1- or β-adrenergic receptor activation in the amygdala indeed recovered

the impaired memory retrieval by LC inhibition, supporting the idea that the retrieval

process of conditioned aversive memory is mediated at least partly through

α_1/β-adrenergic receptor signalling via the LC-amygdalar pathway.

Discussion

We successfully developed INTENS as a novel chemogenetic approach to stimulate the activity of neuronal types of interest. The IR84a/IR8a complex forms an odorant-gated ionotropic cation channel (*Abuin et al., 2011; Benton et al., 2009; Grosjean et al., 2011; Rytz et al., 2013*). The present results confirmed that expression of this complex is sufficient to confer PhAl/PhAc-induced excitatory responses in mammalian cells.

Microinjection of PhAc (0.4 or 0.6%) into the LC results in an increased NE release in the Tg brain and that, in particular, a higher dose of PhAc injection was followed by a sustained elevation of NE release. The IR84a/IR8a-dependent activation generates principally monovalent cation currents (Na^+ and K^+), but it may also lead to a small amount of Ca^{2+} entry (*Abuin et al., 2011*). The intracellular signalling cascades mediated by Ca^{2+} influx may contribute to the sustained elevation of NE release after the high-dose PhAc injection. For instance, Ca^{2+}/calmodulin-dependent protein kinase II and protein kinase C mediate trafficking of glutamate receptors and long-term plasticity dependent on protein synthesis (*Herring and Nicoll, 2016; MacDonald et al., 2001*). Activation of protein kinase C also promotes TH gene expression and NE biosynthesis

in catecholamine-producing cells (*Goc et al., 1992; Vyas et al., 1990*).

The system of designer receptors exclusively activated by designer drugs has

provided a representative chemogenetic strategy that stimulates or inhibits the activity

of specific neuronal types (*Roth, 2016; Urban and Roth, 2015*). In this system, the

engineered metabotropic receptors are expressed in the target neuronal type and

clozapine N-oxide (CNO), a ligand for the engineered receptors, is administered.

However, CNO-induced cellular responsiveness requires G proteins and relevant second

messenger cascades that exist endogenously in each neuronal type. In addition, CNO

has multiple dose-dependent effects on wild-type animals through *in vivo* conversion to

clozapine and N-desmethylclozapine, which act on several types of G protein-coupled

receptors (*MacLaren et al., 2016*) , and the converted clozapine appears to bind the

engineered receptors (*Gomez et al., 2017*). By contrast, our INTENS technology

depends on the expression of foreign ligand-gated excitatory IRs, which are directly

activated by PhAl/PhAc, in specific neurons, and does not require other signalling

systems. In our technology, a higher dose of ligands (0.6% PhAc) can induce a

long-term sustained activation of cellular responsiveness. Furthermore, systemic

administration of a ligand precursor enables the stimulation of the neurons in the brain.

This technology thus provides a powerful strategy that stimulates the target neuronal

activity using the invertebrate-derived ionotropic receptors to study behavioral and

physiological roles of neuronal types of interest. Although we used just one type of IR

complex here, this family of olfactory receptors represents a large, and functionally

divergent, family of ion channel receptors (*Croset et al., 2010*), other members of this

group may be useful for different applications of INTENS. The inhibitory strategy of

neuronal activity has been reported using an ivermectin-sensitive chloride channel

(*Lerchner et al., 2007; Slimko et al., 2002*).

The present findings provide clear evidence for the key role of LC NE neurons

in the retrieval process of conditioned taste aversion, which requires amygdalar function.

A previous study with dopamine β-hydroxylase-deficient mice reports that NE

transmission is involved in the retrieval of intermediate-term contextual fear and spatial

memory requiring the hippocampus (*Murchison et al., 2004*), whereas pharmacological

blockade of β-adrenergic receptors in the amygdala does not influence the recall of

conditioned odour aversion that depends on the association between an odour stimulus

and a visceral malaise-inducing stimulus (*Miranda et al., 2007*). Conditioned odour

aversion also requires amygdalar function (*Ferry and Di Scala, 1997*), and the

acquisition of this aversion is disrupted by catecholamine depletion of amygdala

(*Fernandez-Ruiz et al., 1993*) or blockade of β-adrenergic receptor in the amygdala

(*Miranda et al., 2007*), suggesting a distinct mechanism on the maintenance or retrieval

of conditioned aversive memory between sensory modalities. In addition, electrical LC

stimulation facilitates memory retrieval of the maze performance (*Devauges and Sara,*

1991; Sara and Devauges, 1988), although the target brain regions affected by LC

activity have not been identified. A functional magnetic resonance imaging study also

indicates the LC response at the retrieval of events learned in an emotional context in

humans (*Sterpenich et al., 2006*). These data suggest the engagement of LC NE

neurons in the retrieval process of different types of memory.

The facilitative role of LC NE neurons in the retrieval process of taste aversion

was mediated through α_1- and β-adrenergic receptors via LC-amygdalar pathway. LC

NE neurons send their axon terminals to nuclei in the amygdala, including the

basolateral and central nuclei (*Chandler et al., 2014; Robertson et al., 2013*). The

basolateral nucleus shows the importance in conditioned taste aversion

(*Bermúdez-Rattoni, 2004; Yamamoto et al., 1994*), whereas some studies indicate the

requirement of the central nucleus for taste aversion (*Baha et al., 2003; Lamprecht et*

al., 1997), although there are controversial results for this requirement (*Yamamoto et*

al., 1995). In this study, the coordinates used for the intra-amygdala injection were

localized within the basolateral amygdala. However, we could not exclude the

possibility that the injected drug solution may expand to other amygdala nuclei, such as

the central nucleus, so we did not distinguish the function in the retrieval of taste

memory between the basolateral and central nuclei of the amygdala. LC NE neurons

innervate mainly to the pyramidal neurons in the basolateral amygdala together with a

small number of presumptive interneurons (*Zhang et al., 2013*). NE potentiates

excitatory synaptic transmission through some presynaptic mechanisms via

β-adrenergic receptors (*Ferry et al., 1997; Huang et al., 1996*) and inhibitory synaptic

transmission through presynaptic α_1-adrenoceptors (*Braga et al., 2004*). In addition, *in*

vivo electrophysiological studies report that LC stimulation or NE iontophoresis

produces excitatory or inhibitory responses of basolateral amygdalar neurons (*Buffalari*

and Grace, 2007; Chen and Sara, 2007). These potential synaptic mechanisms may

underlie the facilitation of memory retrieval dependent on the activation of the

LC-amygdalar pathway. In addition, recent studies report that dopamine is released

from LC terminals in the hippocampus and that LC-derived dopamine modulates

memory formation (*Kempadoo et al., 2016; Takeuchi et al., 2016*). Similarly, dopamine

may be released from LC terminals in the amygdala and partly implicated in the

retrieval process of amygdala-dependent memory. This issue needs to be addressed in

the future.

In conclusion, the present study provides evidence that the LC-amygdalar

pathway, through α1- and β-adrenergic receptor signalling, is essential and sufficient for

enhancing the retrieval process of conditioned taste aversion memory. We focused on

the study of LC NE function in taste aversion circuits, and we need to investigate

whether the finding on the role of these neurons in memory recall is applicable for other

types of memory paradigms. Dysfunction of the central NE system is implicated in the

pathological states of neuropsychiatric diseases, such as Korsakoff's syndrome with

anterograde and retrograde amnesia, post-traumatic amnesia, and post-traumatic stress

disorder (*Chamberlain and Robbins, 2014; Hendrickson and Raskind, 2016*).

Adrenergic receptor subtypes are potential therapeutic targets for post-traumatic stress

disorder (*Strawn and Geracioti, 2008*). A detailed analysis of the neural substrate that

mediates memory retrieval dependent on the LC-amygdalar NE system may provide

insight leading to a deeper understanding of the mechanisms underlying the

pathogenesis of these neuropsychiatric diseases.

Contact for resources and reagents sharing

Further information and requests for resources and reagents should be directed to and

will be fulfilled by the Lead Contact, Kazuto Kobayashi (kazuto@fmu.ac.jp).

Materials and methods

Tg mouse strain

A gene cassette encoding a chimeric protein composed of GFP-IR84a-2A-IR8a with a

human calreticulin signal peptide was exchanged by the GFP cDNA part of the plasmid

pTH-GFP that contains a 9-kb rat TH gene promoter, rabbit β-globin second intron,

GFP cDNA, and rabbit β-globin and SV40 early gene polyadenylation signals

(*Sawamoto et al., 2001*), resulting in the plasmid pTH-GFP-IR84a/IR8a. The transgene

construct was linearized by *Sal*I digestion, purified by a gel electrophoresis, and

microinjected into fertilized C57BL/6J mouse eggs, which were then implanted into

pseudopregnant females. Tg mice were identified by Southern blot hybridization or

polymerase chain reaction with genomic DNA prepared from tail clips. Mice aged

12-14 weeks old were used for the following experiments except for *in vitro*

electrophysiology, in which mice aged 17-20 postnatal days were used. Assignment of

animals to the following experimental conditions was random.

Histology

Mice were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal) and

perfused transcardially with PBS, followed by fixation with 4% paraformaldehyde in

0.1 M phosphate buffer (pH 7.4). Sections (30 μm thick) were incubated with a primary

antibody for GFP (rabbit, 1:2,000, Invitrogen) and then with a biotinylated secondary

antibody (anti-rabbit IgG, 1:500, Jackson ImmunoResearch Laboratories). The

immunoreactive signals were visualized by use of a Vectastain Elite ABC kit (Vector

Laboratories) with 3,3□-diaminobenzidine tetrahydrochloride/H_2O_2 as a chromogen.

For double-fluorescence histochemistry, sections were incubated with anti-TH antibody

(mouse, 1:400, Millipore) and anti-GFP antibody (rabbit, 1:2,000, ThermoFisher) or

anti-NET antibody (mouse, 1:2,000) and anti-IR8a antibody (rabbit, 1 μg/ml). Anti-IR8a

antibody was prepared by immunization with purified protein of

glutathione-S-transferase fused to a 27-amino acid fragment of IR8a

(DKYSPYSSRNNRQAYPVACREFTLRES). The specificity of anti-IR8a antibody was

confirmed by double-fluorescence immunohistochemistry for NET/IR8a with LC

sections prepared from the Tg and non-Tg mice. The sections were incubated with

species-specific secondary antibodies conjugated to Alexa488 (Molecular Probes) and

Cy3 (Jackson ImmunoResearch). Fluorescent images were visualized under a confocal

laser-scanning microscope (LSM510 or LSM800, Zeiss) equipped with proper filter

cube specifications.

For cell counts of double-fluorescence histochemistry for TH and GFP, 4 sections

through the LC along with the anteropoterior coordinates (mm) between -5.43 and -5.68

from bregma were prepared from each mouse and used for double immunostaining. The

number of immuno-positive cells in the region of interest (200×200 μm) was counted by

using a computer-assisted imaging program (NIH Image 1.62, National Institutes of

Health), and the number of TH$^+$/GFP$^+$ cells was divided by that of total TH$^+$ cells in each

section. The average of the percentage obtained from 4 sections was calculated. Four

mice were used for cell counts of the immunostaining.

For *in situ* hybridization, Fresh-frozen sections (10 μm thick) were fixed in a

solution of 4% paraformaldehyde in 0.1 M phosphate buffer and treated with 0.1 M

triethanolamine (pH 8.0) containing 0.25% acetic anhydride. Sections were hybridized

with antisense RNA probe for IR84a (nucleotides 82-780) or IR8a (nucleotides 4-529)

sequence labelled using *in vitro* transcription with digoxigenin-11-UTP (Roche). The

signals were visualized with a nonradioactive detection system using anti-digoxigenin

Fab fragment conjugated to alkaline phosphatase (Roche).

To validate the cytotoxicity of PhAc treatment, sections through the LC were

prepared from the Tg mice 7 days after unilateral treatment with PBS or PhAc (0.4/0.6%)

for the microdialysis analysis, and stained for TH and NET immunohistochemistry. The

ratio of the number of cells stained for TH or NET in the treated side relative to the intact

side was calculated. In the experiment for the staining with cell death markers, ibotenic

acid (IBO, 1 mg/ml, as positive controls to detect cell death signals) or PhAc (0.6%) was

injected into the LC (0.2 µl/site) in either hemisphere of the Tg mice. The LC sections

were stained with terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end

labeling (TUNEL) or immunostaining for activated caspase-3, together with counter

staining with 4',6-diamidino-2-phenylindole (DAPI).

Electrophysiology

For slice electrophysiology, mice were anesthetized with 1.5% isoflurane. Coronal brain

slices containing the LC were cut (300 µm thick) using a microslicer (PRO7, Dosaka) in

ice-cold oxygenated cutting Krebs solution of the following composition (mM): choline

chloride, 120, KCl, 2.5, $NaHCO_3$, 26, NaH_2PO_4, 1.25, D-glucose, 15, ascorbic acid, 1.3,

$CaCl_2$, 0.5, and $MgCl_2$, 7. The slices were then transferred to a holding chamber

containing standard Krebs solution of the following composition (mM): NaCl, 124, KCl,

3, $NaHCO_3$, 26, NaH_2PO_4, 1, $CaCl_2$, 2.4, $MgCl_2$, 1.2, and D-glucose, 10 (pH 7.4) when

bubbled with 95% O_2-5% CO_2. Slices were incubated in the holding chamber at room

temperature (21°-26°C) for at least 1 hour before recording. Neurons in the LC were

visualized with a 60× water immersion objective attached to an upright microscope

(BX50WI, Olympus Optics). LC neurons with fluorescence were visualized using the

appropriate fluorescence filter (U-MWIG3, Olympus Optics). Patch pipettes were made

from standard-walled borosilicate glass capillaries (Harvard Apparatus). For the

recording of membrane potentials, a K-gluconate-based internal solution of the

following composition (mM) was used: K-gluconate, 120, NaCl, 6, $CaCl_2$, 5, $MgCl_2$, 2,

K-EGTA, 0.2, K-HEPES, 10, Mg-ATP, 2, and Na-GTP, 0.3 (pH adjusted to 7.4 with 1

M KOH). Whole-cell recordings were made from LC neurons with fluorescence using a

patch-clamp amplifier (Axopatch 200B, Molecular Devices). Data were stored on

digital audiotapes using a DAT recorder (DC to 10 kHz, Sony), and were digitized

off-line at 10 kHz (low-pass filtered at 2 kHz with an 8-pole Bessel filter) using

pCLAMP9 software (Molecular Devices).

NE cells in the LC were identified by low frequency (<7 Hz) action potentials

with large after-hyperpolarization, as described in previous studies (*van den Pol, et al.,*

2002; Zhang et al., 2010). The effects of drugs on the membrane potential were

assessed after the effect had reached the steady state and comparing this value for 30-60

s with that before 30-60 s before drug application. Although a few neurons had firing

frequency greater than 7 Hz (9-10 Hz) before drug application, these neurons were also

included in the analyses due to the characteristic shape of action potentials with large

after-hyperpolarization.

For cultured cell electrophysiology, HEK293T cells were transduced by a

lentiviral vector carrying a fusion gene that encodes EGFP-IR84a and hemagglutinin

(HA)-IR8a connected through 2A peptide under the control of a cytomegalovirus gene

promoter. The ligand-induced currents were measured at room temperature using the

standard whole-cell voltage-clamp technique (*Osanai et al., 2006; Tarradas et al.,*

2013). Borosilicate glass pipettes (4-6 MΩ) were filled with an intracellular solution

containing (mM): 135 K-methanesulfonate, 5 KCl, 0.5 EGTA, 5 Mg-ATP, 0.4 Na-GTP,

and 10 HEPES (pH 7.2, adjusted with KOH), and were used for voltage clamp

recordings. Cells were continuously perfused with a modified Hanks' solution

containing (mM): 137 NaCl, 3 KCl, 1.2 $MgCl_2$, 1.8 $CaCl_2$, 20 glucose, and 10 HEPES

(pH 7.4, adjusted with NaOH after dissolving PhAc). Currents were recorded with an

EPC-10 amplifier (HEKA), and the data were sampled at 2 kHz. Non-transduced

GFP-negative cells were used for the controls. To monitor ligand dose responses, the

amplitudes of the ligand-induced currents were measured at different doses of PhAc and

normalized in each cell to the amplitude at the average of 0.01% PhAc treatment.

An extracellular single-unit recording was carried out *in vivo* (*Takahashi et al.,*

2010). Mice were anesthetized with 1.5% isoflurane and anaesthesia was maintained

with 0.5-1.0% isoflurane based on the monitoring of electroencephalogram. The mice

were placed in the stereotaxic frame (SR-5M, Narishige) with ear bars and a

mouth-and-nose clamp. Body temperature was maintained at 37-38°C with a heating

pad. The scalp was opened, and a hole was drilled in the skull above the LC with the

coordinates in mm anteroposterior (AP) −1.2 and mediolateral (ML) +0.9 from lambda

according to the mouse stereotaxic atlas (*Franklin and Paxinos, 2008*). Two skull

screws were placed over the occipital bone and another skull screw was placed on the

frontal bone. One of the two screws over the occipital bone was used as a reference for

the recording. For pneumatic injection, the firing activity was recorded by a

double-barrel glass pipette, in which the tip of the injection capillary (tip diameter:

50μm, A&M systems) was glued ~100 μm above the tip of the recording electrode (tip

diameter: 2-3 μm, impedance: 15-20 MΩ, Harvard Apparatus). The pipette was lowered

into the LC, dorsoventral (DV) −2.2 to −3.5 mm from dura, and recording was

performed using Spike2 (Cambridge Electronic Design) at a sampling rate of 20 kHz.

NE neurons were identified based on a slow tonic firing (< 6 Hz) with long spike

duration (> 0.8 ms) as described (*Takahashi et al., 2010*). Solution of 1% PhAc was

delivered into the LC through a pneumatic pump (PV-820, World Precision Instruments).

For systemic administration of ligand precursor, MPhAc was dissolved in PBS

containing 1.5% Tween 80 and 2.5% ethanol. Solution of MPhAc (20 mg/kg) or vehicle

(5 ml/kg) was administered in the lateral tail vein and the *in vivo* recording was

performed as described above, except for the use of the recording electrode without the

injection capillary. The effects of systemic administration were assessed 10 min after

the onset of tail vein injection (~50 min). After the electrophysiological experiments,

the recording sites were marked by iontophoretic injection of 2% pontamine sky blue.

The mice were deeply anesthetized with sodium pentobarbital and perfused

transcardially with PBS, followed by 10% formaline. Brain sections were stained with

neutral red for the verification of recording sites. The post-mortem histological analysis

verified deposits of recording sites in the LC (*Figure 2—figure supplement 2A*).

Microdialysis

Mice were anesthetized with 1.5% isoflurane and underwent unilaterally stereotaxic

surgery with a 25-gauge guide cannula (Eicom) for a dialysis probe aimed at ACC or

the amygdala as well as a 30-gauge guide cannula (Eicom) for injection into the LC at

the ipsilateral side. The coordinates (mm) from bregma or dura were AP +0.7, ML +0.3,

and DV −0.4 for the ACC dialysis probe, AP −1.2, ML +3.5, DV −3.5 for the amygdala

dialysis probe, and AP −0.75, ML +0.65, and DV −2.5 for the LC microinjection,

according to the mouse stereotaxic atlas (*Franklin and Paxinos, 2008*). Two or three

days later, the stylet in the cannula was replaced with an active membrane dialysis

probe (1.0 mm in length, 0.22 mm in outer diameter, Eicom) that was connected to a

2,500 μl syringe filled with artificial cerebrospinal fluid (aCSF) of the following

composition (mM): NaCl, 148, KCl, 4.0, $MgCl_2$, 0.85, and $CaCl_2$, 1.2. For the intra-LC

injection, the stylet in the LC cannula was replaced with a 35-gauge internal cannula (1

mm beyond the tip of the implanted guide cannula, Eicom) connected to a 10 μl

Hamilton syringe, aCSF was pumped through the probe at a rate of 1.0 μl/min for 2 h,

and then dialysis samples were collected every 30 min using a refrigerated fraction

collector (EFC-82, Eicom). Each sample vial contained 10 μl of antioxidant, which

consisted of 20 mM phosphate buffer including 25 mM EDTA-2Na and 0.5 mM of

ascorbic acid (pH 3.5). Three baseline samples were collected to measure a tonic level

of NE. This was followed by PhAc (0.4/0.6%) or PBS injection into the LC for 5 min to

a total volume of 0.2 μl. Four samples were collected thereafter to assess the time

course for change in NE level after the injection. The amount of NE in each fraction

was determined by a high-performance liquid chromatography system (CA-50DS, 2.1

mm × 150 mm, Eicom, with the mobile phase containing 5% methanol in 100 mM

sodium phosphate buffer, pH 6.0) equipped with an electrochemical detector (ECD-300,

Eicom). Results are expressed as percentage of baseline concentration (analyte

concentration × 100/mean of the three baseline samples). Systemic administration of

MPhAc (10 mg/kg) or vehicle (5 ml/kg) was administered in the lateral tail vein and

microdialysis samples were collected from the ACC as described above. After the

microdialysis experiments, the mice were deeply anesthetized with sodium

pentobarbital and perfused transcardially with PBS, followed by 10% formaline. Brain

sections were stained with neutral red for the verification of placement sites. The

post-mortem analysis confirmed the placement sites of the injection needle in the LC

and dialysis probes in the ACC and the amygdala (*Figure 2—figure supplement*

2B-D).

Behavioral analysis

Taste reactivity test was carried out as described (*Inui et al., 2013; Yasoshima and*

Shimura, 2017) with some modifications. Mice were anesthetized with 1.5% isoflurane

and, surgically, bilaterally implanted with 26-gauge guide cannulae (Plastics One) into

the LC using the coordinates (mm) AP −0.9, ML +0.6 and DV −2.3 from lambda or

dura according to the brain atlas (*Franklin and Paxinos, 2008*). An intraoral catheter

for infusion of the taste stimulus (0.5 M sucrose dissolved in tap water) was surgically

placed on the left side of the oral cavity, and the inlet of the catheter was fixed with

acrylic cement on the guide cannula assembly. After a 1-week recovery period, the mice

were placed on a 20-h water deprivation schedule. Fluid intake training with tap water

was conducted over 4 days. Consumption was measured by weighing bottles before and

after the 20-min access. The mice were allowed to access water *ad libitum* for 3 h after

the training. The taste aversion paradigm contained three different phases (*Figure 3A*).

In the conditioning phase (days 1 and 2), the mice were presented to 0.5 M sucrose with

the spout as the CS for 20 min, and 10 min later they received an intraperitoneal

injection with 0.15 M LiCl (2% of body weight) as the US. In the habituation phase

(days 3-5), the mice were habituated to intraoral infusion with tap water in the test

chamber. The chamber consisted of an acrylic cylinder (dimensions in mm: diameter,

140, height, 250) and an acrylic box (dimensions in mm: length and width, 325, height,

310) equipped with an inside mirror, which enabled monitoring of the animal's behavior

from the bottom, and the infusion was carried out at the constant flow rate of 50 μl/min

for 15 min by syringe pump (Eicom). On the day of the test phase (day 6), a solution

(0.2 μl/site) containing PhAc (0.4/0.6%) or PBS was injected into the bilateral LC 20

min before CS presentation. The solution was delivered through a 33-gauge internal

cannula (1 mm beyond the tip of the implanted guide cannula, Plastic One) at a flow

rate of 0.05 μl/min. The mice were placed in the test chamber and infused intraorally

with 0.5 M sucrose. Behavior was recorded using a digital video camera, and the

latency for the initiation of rejection responses (including gaping, chin rubbing,

forelimb flailing, paw wiping, and CS dropping) was measured.

For the taste sensitivity test, mice received a bilateral implantation of guide

cannulae into the LC. The mice were placed on a 20-h water deprivation schedule and

conducted the intake training over 4 days. They received microinjection of PBS or 0.6%

PhAc into the bilateral LC (0.2 µl/site) 20 min before the fluid presentation, 0.5 M

sucrose was presented to the mice for 20 min, and the sucrose consumption was

measured.

To monitor hedonic responses, mice were surgically bilaterally implanted with

26-gauge guide cannulas into the LC, and then with an intraoral catheter for infusion of

the taste stimulus on the left oral cavity as described above. The mice were habituated

to the intraoral infusion with tap water in the test chamber. A solution (0.2 µl/site)

containing PBS or 0.6% PhAc was injected into the bilateral LC, 20 min later, the mice

were placed in the test chamber and infused intraorally with 0.5 M sucrose. Behavior

was recorded using a digital video camera, and the latency for the initiation of hedonic

responses (including tongue protruding and lateral tongue protruding) was measured.

To test aversive responses to quinine, mice received a bilateral implantation of

guide cannulae into the LC and a unilateral placement of an intraoral catheter into the

oral cavity. The mice were habituated to the intraoral infusion with tap water in the test

chamber. A solution (0.2 μl/site) containing PBS or 0.6% PhAc was injected into the

bilateral LC, 20 min later, the mice were placed in the test chamber and infused

intraorally with 0.2 mM quinine. Behavior was recorded, and the latency for the

initiation of rejection responses was measured.

Prior to the pharmacological blocking experiment with adrenergic receptor

antagonists, doses of adrenergic receptor antagonists infused into the amygdala were

checked that do not affect the taste reactivity in wild-type mice. The mice were

implanted bilaterally with guide cannulae into the amygdala using the coordinates (AP

−1.2, ML +3.5, DV −2.5 from bregma or dura) according to the mouse brain atlas

(*Franklin and Paxinos, 2008*) and one intraoral catheter on the oral cavity. A solution

(0.2 μl/site) containing PRAZ (0.1 or 0.5 μg/site) or PROP (0.4 or 2.0 μg/site) was

injected bilaterally through an internal cannula into the amygdala, and then the taste

reactivity test was performed as described above. For the blocking experiment, mice

were further implanted surgically with two guide cannulae into the bilateral LC using

the same coordinates as above. A solution (0.2 μl/site) containing PRAZ (0.1 μg/site) or

PROP (0.4 μg/site) was injected bilaterally through an internal cannula into the

amygdala 5 min before bilateral injection of 0.6% PhAc into the LC (0.2 μl/site) for the

taste reactivity test.

For the pharmacological inhibition experiment of LC neuronal activity, mice

were implanted surgically with two guide cannulae into the bilateral LC and one

intraoral catheter into the oral cavity as above. Solution (0.2 μl/site) containing CLO

(10 and 25 ng/site) was injected bilaterally through an internal cannula into the LC and

tested for taste reactivity 20 min later. For the pharmacological recovery, the mice were

further implanted bilaterally with guide cannulae into the amygdala using the same

coordinates as above. A solution (0.2 μl/site) containing MET (0.5 μg/site) or ISO (1.25

μg/site) was injected bilaterally through an internal cannula into the amygdala 5 min

after the bilateral intra-LC injection of CLO (10 ng/site) for the taste reactivity test.

Locomotor activity was measured with a movement analyser equipped with

photo-beam sensors (SV-10, Toyo Sangyou). The number of beam breaks was counted

for every 10-min session. The total number of beam breaks during a 60-min test period

was calculated to evaluate the spontaneous locomotor activity during the pretreatment

(sessions −6 to −1) and the locomotor activity after PBS treatment (sessions 1-6) and

0.6% PhAc treatment (sessions 7-12).

Animal behaviors were scored by the experimenters, who were blind to the

treatment of the animals. After all behavioral testing, mice were anesthetized with

sodium pentobarbital and perfused transcardially with PBS, followed by 10% formaline.

Brain sections were stained with cresyl violet for the verification of placement sites.

Histological examination confirmed the placement sites of internal cannulae within the

target brain regions (*Figure 3—figure supplement 2* for the taste reactivity, sensitivity,

and locomotor activity tests, *Figure 4—figure supplement 1* for the pharmacological

blocking experiments, and *Figure 5—figure supplement 1* for LC inhibition

experiments).

Quantification and statistical analyses

Although no statistical methods were used to predetermine the sample size for each

measure, we employed similar sample sizes to those that were reported in previous

publications from our labs, which are generally accepted in the field. In all statistical

analyses, outliers were defined as data points located outside the range of mean $\pm$ 2SD,

and then two-tailed tests were performed with SPSS ver. 25 (IBM). The reliably of the

results was assessed against a type I error (α) of 0.05. Prior to unpaired t-test, we

assessed equality of variances for two groups with Levene's test, and if this was not the

case, we reported the statistics (F and p), and then corrected the degree of freedom

according to Welch's method. For significant main effects identified in one- and

two-way analyses of variant (ANOVAs), post hoc comparisons were performed with

Tukey HSD test. For significant interactions revealed in two-way ANOVAs, t-tests with

Holm-Bonferroni sequential correction were used post hoc. One, two, and three stars (*)

in figures represent p-value < 0.05, 0.01, and 0.001, respectively.

Acknowledgments

This work was supported by grants-in-aid for Scientific Research on Innovative Areas

Adaptive Circuit Shift (26112002) from the Ministry of Education, Science, Sports, and

Culture of Japan, and Core Research for Evolutional Science and Technology

(JP16gm0310008) of Japan Science and Technology Agency (K.K.), and by an ERC

Consolidator Grant (615094), an HFSP Young Investigator Award (RGY0073/2011), the

SNSF Nano-Tera Envirobot project (20NA21_143082) (R.B.). We are grateful to M.

Kikuchi, N. Sato, H. Hashimoto, and M. Sugawara for technical support during animal

experiments and to T. Kobayashi for helpful illustrations.

Author contributions

Ryoji Fukabori, Conceptualization, Data curation, Formal analysis, Investigation,

Visualization, Writing-original draft, Writing-review and editing; **Yoshio Iguchi,**

Conceptualization; Data curation, Formal analysis, Investigation, Visualization,

Writing-original draft, Writing-review and editing; **Shigeki Kato**, Data curation,

Investigation, Resources, Visualization, Writing-original draft; **Kazumi Takahashi**,

Data curation, Formal analysis, Investigation, Visualization, Writing-original draft;

Satoshi Eifuku, Data curation, Formal analysis, Investigation, Visualization,

Writing-original draft; **Shingo Tsuji**, Data curation, Formal analysis, Investigation,

Visualization, Writing-original draft; **Akihiro Hazama**, Data curation, Formal analysis,

Investigation, Visualization, Writing-original draft; **Motokazu Uchigashima**, Data

curation, Investigation, Resources, Visualization, Writing-original draft; **Masahiko**

Watanabe, Data curation, Investigation, Resources, Visualization, Writing-original

draft; **Hiroshi Mizuma**, Data curation, Formal analysis, Investigation, Visualization,

Writing-original draft; **Yilong Cui**, Data curation, Formal analysis, Investigation,

Visualization, Writing-original draft; **Hirotaka Onoe**, Data curation, Formal analysis,

Investigation, Visualization, Writing-original draft; **Keigo Hikishima**, Data curation,

Formal analysis, Investigation, Visualization, Writing-original draft; **Yasunobu**

Yasoshima, Data curation, Formal analysis, Investigation, Visualization,

Writing-original draft; **Makoto Osanai**, Data curation, Formal analysis, Investigation,

Visualization, Writing-original draft; **Ryo Inagaki,** Data curation, Formal analysis,

Investigation, Visualization, Writing-original draft; **Kohji Fukunaga**, Data curation,

Formal analysis, Investigation, Visualization, Writing-original draft; **Takuma Nishijo**,

Data curation, Formal analysis, Investigation, Visualization, Writing-original draft;

Toshihiko Momiyama, Data curation, Formal analysis, Investigation, Visualization,

Writing-original draft; **Richard Benton**, Conceptualization, Funding acquisition,

Resources, Supervision, Writing-original draft; **Kazuto Kobayashi**, Conceptualization,

Funding acquisition, Resources, Supervision, Validation, Visualization, Writing-original

draft, Writing-review and editing.

Author ORCIDs

Ryoji Fukabori https://orcid.org/0000-0001-7534-8237

Yoshio Iguchi https://orcid.org/0000-0001-8240-3345

Shigeki Kato https://orcid.org/0000-0002-8792-7591

Kazumi Takahashi https://orcid.org/0000-0003-4015-8016

Satoshi Eifuku https://orcid.org/0000-0003-0032-1720

Akihiro Hazama https://orcid.org/0000-0002-1199-8246

Motokazu Uchigashima https://orcid.org/0000-0002-0878-2233

Masahiko Watanabe https://orcid.org/ 0000-0001-5037-7138

Hiroshi Mizuma https://orcid.org/0000-0001-8970-9486

Yilong Cui https://orcid.org/0000-0002-8302-1899

Keigo Hikishima https://orcid.org/0000-0003-1133-1297

Makoto Osanai https://orcid.org/0000-0002-3572-8195

Ryo Inagaki https://orcid.org/0000-0002-0996-5269

Kohji Fukunaga https://orcid.org/0000-0001-8526-2824

Takuma Nishijo https://orcid.org/0000-0003-0533-0132

Toshihiko Momiyama https://orcid.org/0000-0002-3588-9167

Richard Benton https://orcid.org/0000-0003-4305-8301

Kazuto Kobayashi https://orcid.org/0000-0002-7617-2939

Ethics

Animal care and handling procedures were conducted in accordance with the guidelines

established by the Experimental Animal Centre of Fukushima Medical University.

References

Abuin L, Bargeton B, Ulbrich MH, Isocoff EY, Kellenberger S, Benton R. 2011.

Functional architecture of olfactory ionotropic glutamate receptors. *Neuron* **13**:44-60.

DOI: https://doi.org/10.1016/j.neuron.2010.11.042

Aghajanian GK, VanderMaelen CP. 1982. alpha 2-adrenoceptor-mediated

hyperpolarization of locus coeruleus neurons: intracellular studies *in vivo*. *Science*

215:1394-1396. DOI: https://doi.org/10.1126/science.6278591

American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental

Disorders. 5th ed. American Psychiatric Association. DOI:

https://doi.org/10.1176/appi.books.9780890425596

Baha A, Samuel A, Hazvi S, Dudai Y. 2003. The amygdalar circuit that acquires taste

aversion memory differs from the circuit that extinguishes it. *European Journal of*

Neuroscience **17**:1527-1530. DOI: https://doi.org/10.1046/j.1460-9568.2003.02551.x

Bahar A, Samuel A, Hazvi S, Dudai Y. 2003. The amygdalar circuit that acquires taste

aversion memory differs from the circuit that extinguishes it. *European Journal of*

Neuroscience **17**:1527-1530. DOI: https://doi.org/10.1046/j.1460-9568.2003.02551.x

Benton R, Vannice KS, Gomez-Diaz C, Vosshall LB. 2009. Variant ionotropic

glutamate receptors as chemosensory receptors in Drosophila. *Cell* **136**:149-162.

DOI: https://doi.org/10.1016/j.cell.2008.12.001

Bermúdez-Rattoni F. 2004. Molecular mechanisms of taste-recognition memory. *Nature Review Neuroscience* **5**:209-217. DOI: https://doi.org/10.1038/nrn1344

Braga MF, Aroniadou-Anderjaska V, Manion ST, Hough CJ, Li H. 2004. Stress impairs alpha(1A) adrenoceptor-mediated noradrenergic facilitation of GABAergic transmission in the basolateral amygdala. *Neuropsychopharmacology* **29**:45-58. DOI: https://doi.org/10.1038/sj.npp.1300297

Buffalari DM, Grace AA. 2007. Noradrenergic modulation of basolateral amygdala neuronal activity: opposing influences of α-2 and β receptor activation. *Journal of Neuroscience* **27**:12358-12366. DOI: https://doi.org/10.1523/JNEUROSCI.2007-07.2007

Bush DE, Caparosa EM, Gekker A, Ledoux J. 2010. Beta-adrenergic receptors in the lateral nucleus of the amygdala contribute to the acquisition but not the consolidation of auditory fear conditioning. *Frontier of Behavioral Neuroscience* 26:154. DOI: https://doi.org/10.3389/fnbeh.2010.00154

Chamberlain SR, Robbins TW. 2014. Noradrenergic modulation of cognition: therapeutic implications. *Journal of Psychopharmacology* **27**:694-718. DOI:

https://doi.org/10.1177/0269881113480988

Chandler DJ, Gao WJ, Waterhouse BD. 2014. Heterogeneous organization of the locus

coeruleus projections to prefrontal and motor cortices. *Proceedings of the National*

Academy of Sciences of the United States of America **111**: 6816-6821. DOI:

https://doi.org/10.1073/pnas.1320827111

Chen FJ, Sara SJ. 2007. Locus coeruleus activation by foot shock or electrical

stimulation inhibits amygdala neurons. *Neuroscience* **144**:472-481. DOI:

https://doi.org/10.1016/j.neuroscience.2006.09.037

Croset V, Rytz R, Cummins SF, Budd A, Brawand D, Kaessmann H, Gibson TJ,

Benton R. 2010. Ancient protostome origin of chemosensory ionotropic glutamate

receptors and the evolution of insect taste and olfaction. *PLoS Genetics* **6**:e1001064.

DOI: https://doi.org/10.1371/journal.pgen.1001064

Devauges V, Sara SJ. 1991. Memory retrieval enhancement by locus coeruleus

stimulation: evidence for mediation by beta-receptors. *Behavioural Brain Research*

43:93-97. DOI: https://doi.org/10.1016/s0166-4328(05)80056-7

Fernandez-Ruiz J, Miranda MI, Bermúdez-Rattoni F, Druker-Colin R. 1993. Effects of

catecholaminergic depletion of the amygdala and insular cortex on the potentiation of

odor by taste aversions. *Behavioral and Neural Biology* **60**:189-191. DOI:

https://doi.org/10.1016/0163-1047(93)90314-8

Ferry B, Di Scala G. 1997. Bicuculline administration into basolateral amygdala

facilitates trace conditioning of odor aversion in the rat. *Neurobiology of Learning*

and Memory **67**:80-83 (1997). DOI: https://doi.org/10.1006/nlme.1996.3743

Ferry B, Magistretti PJ, Pralong E. 1997. Noradrenaline modulates glutamate-mediated

neurotransmission in the rat basolateral amygdala *in vitro*. *European Journal of*

Neuroscience **9**:1356-1364. DOI:

https://doi.org/10.1111/j.1460-9568.1997.tb01490.x

Ferry B, Parrot S, Marien M, Lazarus C, Cassel JC, McGaugh JL. 2015. Noradrenergic

influences in the basolateral amygdala on inhibitory avoidance memory are mediated

by an action on α2-adrenoceptors. *Psychoneuroendocrinology* **51**:68-79. DOI:

https://doi.org/10.1016/j.psyneuen.2014.09.010

Franklin KBJ, Paxinos G. 2008. The Mouse Brain in Stereotaxic Coordinates. 3rd ed.

Elsevier/Academic Press. ISBN: 9780123742445

Gelinas JN, Nguyen PV. 2005. Beta-adrenergic receptor activation facilitates induction

of a protein synthesis-dependent late phase of long-term potentiation. *Journal of*

Neuroscience **25**:3294-3303. DOI:

https://doi.org/10.1523/JNEUROSCI.4175-04.2005

Goc A, Norman SA, Puchacz E, Stachowiak EK, Lukas RJ, Stachowiak MK. 1992. A

5'-flanking region of the bovine tyrosine hydroxylase gene is involved in

cell-specific expression, activation of gene transcription by phorbol *ester, and*

transactivation by c-Fos and c-Jun. Molecular and Cellular Neuroscience **3**:383-394.

DOI: https://doi.org/10.1016/1044-7431(92)90050-C

Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA,

Ellis RJ, Richie CT, Harvey BK, Dannals RF, and et al. 2017. Chemogenetics

revealed: DREADD occupancy and activation via converted clozapine. *Science*

357:503-507. DOI: https://doi.org/10.1126/science.aan2475

Grosjean Y, Rytz R, Farine JP, Abuin L, Cortot J, Jefferis GS, Benton R. 2011. An

olfactory receptor for food-derived odours promotes male courtship in *Drosophila*.

Nature **478**:236-240. DOI: https://doi.org/10.1038/nature10428

Guzmán-Ramos K, Osorio-Gómez K, Moreno-Castilla P, Bermúdez-Rattoni F. 2012.

Post-acquisition release of glutamate and norepinephrine in the amygdala is involved

in taste-aversion memory consolidation. *Learning and Memory* **19**:231-238. DOI:

https://doi.org/10.1101/lm.024703.111

Hendrickson RC, Raskind MA. 2016. Noradrenergic dysregulation in the

pathophysiology of PTSD. *Experimental Neurology* **284**:181-195. DOI:

https://doi.org/10.1016/j.expneurol.2016.05.014

Herring BE, Nicoll RA. 2016. Long-term potentiation: from CaMKII to AMPA

receptor trafficking. *Annual Review of Physiology* **78**:351-365. DOI:

https://doi.org/10.1146/annurev-physiol-021014-071753

Huang CC, Hsu KS, Gean PW. 1996. Isoproterenol potentiates synaptic transmission

primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium

channels in the rat amygdala. *Journal of Neuroscience* **16**:026-1033. DOI:

https://doi.org/10.1523/jneurosci.16-03-01026.1996

Huang YY, Kandel ER. 2007. Low-frequency stimulation induces a pathway-specific

late phase of LTP in the amygdala that is mediated by PKA and dependent on protein

synthesis. *Learning and Memory* **14**:497-503. DOI:

https://doi.org/10.1101/lm.593407

Huang YY, Martin KC, Kandel ER. 2000. Both protein kinase A and mitogen-activated

protein kinase are required in the amygdala for the macromolecular

synthesis-dependent late phase of long-term potentiation. *Journal of Neuroscience*

20:6317-6325. DOI: https://doi.org/10.1523/jneurosci.20-17-06317.2000

Huang YY, Kandel ER. 1996. Modulation of both the early and the late phase of mossy

fiber LTP by the activation of beta-adrenergic receptors. *Neuron* **16**:611-617. DOI:

https://doi.org/10.1016/s0896-6273(00)80080-X

Inui T, Inui-Yamamoto C, Yoshioka Y, Ohzawa I, Shimura T. 2013. Activation of

efferents from the basolateral amygdala during the retrieval of conditioned taste

aversion. *Neurobiology of Learning and Memory* **106**:210-220. DOI:

https://doi.org/0.1016/j.nlm.2013.09.003

Johansen JP, Diaz-Mataix L, Hamanaka H, Ozawa T, Ycu E, Koivumaa J, Kumar A,

Hou M, Deisseroth K, Boyden ES, et al. 2014. Hebbian and neuromodulatory

mechanisms interact to trigger associative memory formation. *Proceedings of the*

National Academy of Sciences of the United States of America **111**:5584-5592. DOI:
https://doi.org/10.1073/pnas.1421304111

Kempadoo KA, Mosharov EV, Choi SJ, Sulzer D, Kandel ER. 2016. Dopamine release

from the locus coeruleus to the dorsal hippocampus promotes spatial learning and

memory. *Proceedings of the National Academy of Sciences of the United States of*

America **113**:14835-14840. DOI: https://doi.org/10.1073/pnas.1616515114

Klein SB, Nichols S. 2012. Memory and the sense of personal identity. *Mind*

121:677-702. DOI: https://doi.org/10.2307/23321780

Kobayashi K, Noda, Y, Matsushita N, Nishii K, Sawada H, Nagatsu T, Nakahara D,

Fukabori R, Yasoshima Y, Yamamoto T, et al. 2000. Modest neuropsychological

deficits caused by reduced noradrenaline metabolism in mice heterozygous for a

mutated tyrosine hydroxylase gene. *Journal of Neuroscience* **15**:2418-2426. DOI:

https://doi.org/10.1523/JNEUROSCI.20-06-02418.2000

Kopelman MD. 1992. The psychopharmacology of human memory disorders. In

Clinical Management of Memory Problems, eds Wilson B., Moffat N. 189-215

Springer. DOI: https://doi.org/10.1007/978-1-4899-4523-5

LaLumiere RT, Buen TV, McGaugh JL. 2003. Post-training intra-basolateral amygdala

infusions of norepinephrine enhance consolidation of memory for contextual fear

conditioning. *Journal of Neuroscience* **23**:6754-6758. DOI:

https://doi.org/10.1523/JNEUROSCI.23-17-06754.2003

Lamprecht R, Hazvi S, Dudai Y. 1997. cAMP response element-binding protein in the

amygdala is required for long- but not short-term conditioned taste aversion memory.

Journal of Neuroscience **17**:8443-8450. DOI:

https://doi.org/10.1523/jneurosci.17-21-08443.1997

Lerchner W, Xia C, Nashmi R, Slimko EM, van Trigt L, Lester HA, Anderson DJ.

2007. Reversible silencing of neuronal excitability in behaving mice by a genetically

targeted, ivermectin-gated Cl- channel. *Neuron* **54**:35-49. DOI:

https://doi.org/10.1016/j.neuron.2007.02.030

MacDonald JF, Kotecha SA, Lu VVY, Jackson MF. 2001. Convergence of

PKC-dependent kinase signal cascades on NMDA receptors. *Current Drug Targets*

2:299-312. DOI: https://doi.org/10.2174/1389450013348452

MacLaren DAA, Browne RW, Shaw JK, Radhakrishnan SK, Khare P, Espana RA,

Clark SD. 2016. Clozapine N-oxide administration produces behavioral effects in

Long-Evans rats: implications for designing DREADD experiments. *eNeuro*

3:e0219-16.2016. DOI: https://doi.org/10.1523/ENEURO.0219-16.2016

Miranda MA, Ferry B, Ferreira G. 2007. Basolateral amygdala noradrenergic activity

is involved in the acquisition of conditioned odor aversion in the rat. *Neurobiology of*

Learning and Memory **88**:260-263. DOI: https://doi.org/10.1016/j.nlm.2007.04.008

Murchison CF, Zhang XY, Zhang WP, Ouyang M, Lee A, Thomas SA. 2004. A distinct

role for norepinephrine in memory retrieval. *Cell* **117**:131-143. DOI:

https://doi.org/10.1016/s0092-8674(04)00259-4

O'Dell TJ, Connor SA, Gelinas JN, Nguyen PV. 2010. Viagra for your synapses:

Enhancement of hippocampal long-term potentiation by activation of beta-adrenergic

receptors. *Cellular Signalling* **22**:728-736. DOI:

https://doi.org/10.1016/j.cellsig.2009.12.004

Osanai M, Saegusa H, Kazuno A, Nagayama S, Hu Q, Zong S, Murakoshi T, Tanabe T.

2006. Altered cerebellar function in mice lacking $Ca_V2.3$ Ca^{2+} channel. *Biochemical*

and Biophysical Research Communications **344**:920-925. DOI:

https://doi.org/10.1016/j.bbrc.2006.03.206

Robertson SD, Plummer NW, de Marchena J, Jensen P. 2013. Developmental origins of

central norepinephrine. *Nature Neuroscienc*e **16**:1016-1023. DOI:

https://doi.org/10.1038/nn.3458

Roth BL. 2016. DREADDs for neuroscientists. *Neuron* **89**:683-694. DOI:

https://doi.org/10.1016/j.neuron.2016.01.040

Rytz R, Croset V, Benton R. Ionotropic receptors (IRs): chemosensory ionotropic

glutamate receptors in Drosophila and beyond. (2013). *Insect Biochemistry and*

Molecular Biology **43**:888-897. DOI: https://doi.org/10.1016/j.ibmb.2013.02.007

Sara SJ, Devauges V. 1988. Priming stimulation of locus coeruleus facilitates memory

retrieval in the rat. *Brain Research* **438**:299-303. DOI:

https://doi.org/10.1016/0006-8993(88)91351-0

Sawamoto K, Nakao N, Kobayashi K, Matsushita N, Takahashi H, Kakishita K,

Yamamoto A, Yoshizaki T, Terashima T, Murakami F, and et al. 2001. Visualization,

direct isolation, and transplantation of midbrain dopaminergic neurons. *Proceedings*

of the National Academy of Sciences of the United States of America **98**:6423-6428.

DOI: https://doi.org/10.1073/pnas.111152398

Shukuri M, Takashima-Hirano M, Tokuda K, Takashima T, Matsumura K, Inoue O,

Doi H, Suzuki M, Watanabe Y, Onoe H. 2011. In vivo expression of

cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation

visualized by PET with ^{11}C-ketoprofen methyl ester. *Journal of Nuclear Medicine*

52:1094-1101. DOI: https://doi.org/10.2967/jnumed.110.084046

Slimko EM, McKidnney S, Anderson DJ, Davidson N, Lester HA. 2002. Selective

electrical silencing of mammalian neurons in vitro by the use of invertebrate

ligand-gated chloride channels. *Journal of Neuroscience* **22**:7373-7379. DOI:

https://doi.org/10.1523/JNEUROSCI.22-17-07373.2002

Sterpenich V, D'Argembeau A, Desseilles M, Balteau E, Albouy G, Vandewalle G,

Degueldre C, Luxen A, Collette F, Maquet P. 2006. The locus ceruleus is involved in

the successful retrieval of emotional memories in humans. *Journal of Neuroscience*

26:7416-7423. DOI: https://doi.org/10.1523/JNEUROSCI.1001-06.2006

Strawn JR, Geracioti TD Jr. 2008. Noradrenergic dysfunction and the

psychopharmacology of posttraumatic stress disorder. *Depress Anxiety* **25**:260-271.

DOI: https://doi.org/10.1002/da.20292

Suzuki M, Doi H, Hosoya T, Långström B, Watanabe Y. 2004. Rapid methylation on

carbon frameworks leading to the synthesis of a PET tracer capable of imaging a

novel CNS-type prostacyclin receptor in living human brain. *Trends in Analytical*

Chemistry **23**:595-607. DOI: https://doi.org/10.1016/j.trac.2004.06.003

Takahashi K, Kayama Y, Lin JS, Sakai K. 2010. Locus coeruleus neuronal activity

during the sleep-waking cycle in mice. *Neuroscience* **169**:1115-1126. DOI:

https://doi.org/10.1016/j.neuroscience.2010.06.009

Takashima-Hirano M, Shukuri M, Takashima T, Goto M, Wada Y, Watanabe Y, Onoe

H, Doi H, Suzuki M. 2010. General method for the ^{11}C-labeling of 2-arylpropionic

acids and their esters: construction of a PET tracer library for a study of biological

events involved in COXs expression. *Chemistry* **16**:4250-4258. DOI:

https://doi.org/10.1002/chem.200903044

Takeuchi T, Duszkiewicz AJ, Sonnrborn A, Spooner PA, Yamasaki M, Watanabe M,

Smith CC, Fernandez G, Deisseroth K, Greene RW, Morris RG. 2016. Locus

coeruleus and dopaminergic consolidation of everyday memory. *Nature* **537**:357-362.

DOI: https://doi.org/10.1038/nature19325

Tarradas A, Selga E, Beltran-Alvarez P, Pérez-Serra A, Riuró H, Picó F, Iglesias A,

Campuzano O, Castro-Urda V, Fernández-Lozano I, and et al. 2013. A novel

missense mutation, I890T, in the pore region of cardiac sodium channel causes

Brugada syndrome. *PLoS One* **8**:e53220. DOI:

https://doi.org/10.1371/journal.pone.0053220

Urban DJ, Roth BL. 2015. DREADDs (designer receptors exclusively activated by

designer drugs): chemogenetic tools with therapeutic utility. *Annual Review of*

Pharmacology and Toxicology **55**:399-417. DOI:

https://doi.org/10.1146/annurev-pharmtox-010814-124803

van den Pol AN, Ghosh PK, Liu RJ, Li Y, Aghajanian GK. 2002. Hypocretin (orexin)

enhances neuron activity and cell synchrony in developing mouse GFP-expressing

locus coeruleus. *Journal of Physiology* (Lond) **541**:169-185. DOI:

https://doi.org/10.1113/jphysiol.2002.017426

Villain H, Benkahoul A, Drougard A, Lafragette M, Muzotte E, Pech S, Bui E, Brunet

A, Birmes P, Roullet P. 2016. Effects of propranolol, a β-noradrenergic antagonist, on

memory consolidation and reconsolidation in mice. *Frontier of Behavioral*

Neuroscience **10**:49. DOI: https://doi.org/10.3389/fnbeh.2016.00049

Vyas S, Faucon Biquet N, Mallet J. 1990. Transcriptional and post-transcriptional

regulation of tyrosine hydroxylase gene by protein kinase C. *EMBO Journal*

9:3707-3712. DOI: https://doi.org/10.1002/j.1460-2075.1990.tb07583.x

Warrington EK, Weiskrantz L. 1970. Amnesic syndrome: consolidation or retrieval?

Nature **228**:628-630. DOI: https://doi.org/10.1038/228628a0

Washburn M, Moises HC. 1989. Electrophysiological correlates of presynaptic alpha

2-receptor-mediated inhibition of norepinephrine release at locus coeruleus synapses

in dentate gyrus. *Journal of Neuroscience* **9**:2131-2140. DOI:

https://doi.org/10.1523/jneurosci.09-06-02131.1989

Yamamoto T, Fujimoto Y, Shimura T, Sakai N. 1995. Conditioned taste aversion in rats

with excitotoxic brain lesions. *Neuroscience Research* **22**:31-49. DOI:

https://doi.org/10.1016/0168-0102(95)00875-t

Yamamoto T, Shimura T, Sako N, Yasoshima Y, Sakai N. 1994. Neural substrates for

conditioned taste aversion in the rat. *Behavioural Brain Research* 65:123-137. DOI:

https://doi.org/10.1016/0166-4328(94)90097-3

Yasoshima Y, Shimura T. 2017. Midazolam impairs the retrieval of conditioned taste

aversion via opioidergic transmission in mice. *Neuroscience Letters* **636**:64-69. DOI:

https://doi.org/10.1016/j.neulet.2016.10.055

Zhang J, Muller JF, McDonald AJ. 2013. Noradrenergic innervation of pyramidal cells

in the rat basolateral amygdala. *Neuroscience* **228**:395-408. DOI:

https://doi.org/10.1016/j.neuroscience.2012.10.035

Zhang X, Cui N, Wu Z, Su J, Tadepalli JS, Sekizar S, Jiang C. 2010. Intrinsic

membrane properties of locus coeruleus neurons in Mecp2-null mice. *American

Journal of Physiology Cell Physiology* **298**:C635-C646. DOI:

https://doi.org/10.1152/ajpcell.00442.2009

Zhou J, Luo Y, Zhang JT, Li MX, Wang CM, Guan XL, Wu PF, Hu ZL, Jin Y, Ni L, et

al. 2015. Propranolol decreases retention of fear memory by modulating the stability

of surface glutamate receptor GluA1 subunits in the lateral amygdala. *British Journal

of Pharmacology* **172**:5068-5082. DOI: https://doi.org/10.1111/bph.13272

3 **Figure 1.** Experimental strategy, transgene expression, and ligand-induced LC

4 activation in Tg mice. (**A**) Strategy for INTENS. Tg animals expressing IR84a/IR8a

5 genes in specific cell types are treated with exogenous ligands into the target brain

regions. (**B**) Structure of the gene cassette encoding EGFP-IR84a-2A-IR8a with a signal

peptide (SP) downstream of the TH gene promoter. B, *Bam*HI, E, *Eco*RI, H, *Hin*dIII, S,

*Sal*I. pA, polyadenylation signal. (**C**) Transgene expression in the LC revealed by GFP

immunohistochemistry. 4V: fourth ventricle. (**D**) Confocal microscopic images of LC

sections obtained from double immunohistochemistry for TH/GFP and NET/IR8a. Scale

bars: 500 μm (C), 20 μm (D). (**E**) Schematic illustration of strategy for a whole-cell

current-clamp recording of a brain slice preparation. (**F**) Excitatory effect of PhAl

(0.1%) on the membrane potential of a NE neuron obtained from a Tg mouse. (**G**) Lack

of effect of PhAl (0.1%) on the membrane potential of a neuron from a non-Tg mouse.

(**H**) Excitatory effect of PhAc (0.1%) on the membrane potential of a NE neuron

obtained from a Tg mouse. (**I**) Depolarization block after excitatory response to PhAc in

another neuron in a Tg mouse. (**J**) Lack of effect of PhAc (0.2%) on the membrane

potential of a neuron from a non-Tg mouse. (**K, L**) Bar graphs showing the firing

frequency before and after PhAl application (K) and amplitude of PhAl-induced

depolarization (L) of NE neurons in Tg (n = 11) and non-Tg (n = 4) mice. **$p < 0.01$, vs

pretreatment in Tg mice (paired two-tailed t-test). ***$p < 0.001$ vs. non-Tg mice

(unpaired two-tailed t-test). (**M, N**) Bar graphs showing the firing frequency before and

after PhAc application (M) and amplitude of PhAc-induced depolarization (N) of NE

neurons in Tg (n = 12 for firing frequency and n = 17 for depolarization amplitude) and

non-Tg (n = 4) mice. *$p < 0.05$ vs. pretreatment in Tg mice (paired two-tailed t-test),

***$p < 0.001$ vs. non-Tg mice (unpaired two-tailed t-test). Data are presented as mean $\pm$

SEM. Individual data points are overlaid.

Figure 2. *In vivo* LC activation and increased NE release in Tg mice. (**A**) Schematic

diagram for the strategy of single-unit recording. PhAc solution was pneumatically

injected through a glass capillary attached to the recording electrode. (**B**) Firing pattern

of an identified NE neuron in the Tg (upper panel) and non-Tg (lower panel) mice.

Timing of PhAc injection is indicated. (**C**) Firing rate before and after PhAc injection in

the Tg (n = 6) and non-Tg (n = 5) mice. ***p < 0.001 (paired two-tailed t-test). (**D**)

Firing rate of non-NE neurons with low and high frequency of the activity before and

after PhAc injection in the Tg mice (n = 5 or 7 for each type). (**E**) Diagram for the

microdialysis for measuring NE release in response to LC activation. PhAc solution

(0.4/0.6%) or PBS was injected into the LC, and dialysis samples were collected from

the ACC. (**F**) Changes in the extracellular NE level after PhAc injection in the Tg and

non-Tg mice. NE levels are expressed as a percentage of each animal's average baseline

levels. n = 6 for each group. $*p < 0.05$, $***p < 0.001$ vs PBS, $^{\dagger}p < 0.05$, $^{\dagger\dagger}p < 0.01$ vs

0.4% PhAc (Holm-Bonferroni test). (**G**) Schematic illustration of *in vivo* conversion of

the precursor to the exogenous ligand. MPhAc is systemically administered and

transferred across the blood-brain barrier. MPhAc is metabolized in the brain by

esterase activity into PhAc, which stimulates IR84a/8a complex. (**H**) Firing activity of

LC neurons in the Tg mice before and after systemic administration of MPhAc (n = 5 or

7 for each group) or vehicle (n = 6 or 7 for each group). $*p < 0.05$ vs pretreatment of

MPhAc-administered mice (unpaired two-tailed t-test). (**I**) Extracellular NE level after

systemic injection of MPhAc or vehicle. NE levels expressed as a percentage of each

animal's average baseline levels. n = 4 for each group. $**p < 0.01$, $***p < 0.001$ vs

vehicle-injected Tg mice, $^{\dagger}p < 0.05$, $^{\dagger\dagger\dagger}p < 0.001$ vs MPhAc-injected non Tg mice

1   (Holm-Bonferroni test). Data are presented as mean ± SEM.

Figure 3. Ligand-induced LC activation enhances taste memory retrieval. (**A**) Schedule

of the taste reactivity test. In the conditioning phase, mice were presented 0.5 M sucrose

as the CS, followed by an intraperitoneal injection with 0.15 M LiCl as the US. Then,

the mice were habituated to intraoral infusion with tap water in the test chamber. During

the test phase, mice received a bilateral LC injection of PBS or solution containing

PhAc (0.4/0.6%) followed by CS presentation to evaluate the rejection response. (**B**)

Experimental apparatus used for the taste reactivity test. A mouse was placed in the test

chamber and infused intraorally through a syringe pump, and animal's behavior was

monitored from the bottom through an inside mirror using a digital video camera. (**C**)

Taste reactivity test showing shorter latency of rejection response by ligand-induced LC

activation in Tg mice. n = 8 or 9 for each group in Tg mice. n = 8-11 for each group in

non-Tg mice. *p < 0.05, **p < 0.01 vs PBS in Tg mice (Tukey HSD test). (**D**) Taste

sensitivity test presenting normal intake of 0.5 M sucrose in unconditioned mice. PBS

or PhAc solution (0.6%) was bilaterally injected into the LC, and the fluid intake of 0.5

M sucrose was measured. n = 4-7 for each group. (**E**) Taste reactivity test showing

normal hedonic responses to 0.5 M sucrose in unconditioned Tg mice. PBS or PhAc

solution (0.6%) was bilaterally injected into the LC, and the latency for hedonic

responses was measured. n = 6 for each group. (**F**) Taste reactivity test displaying

unaltered aversive responses to 0.2 mM quinine in unconditioned Tg mice. PBS or

PhAc solution (0.6%) was injected into the LC, and the latency for rejection responses

was measured. n = 8 for each group. (**G**) Locomotor activity. The number of beam

breaks was counted for every 10-min session. The total number of beam breaks during a

60-min test period was calculated as locomotor activity during the pretreatment (Pre)

and after PBS treatment (blocks 1-6) and the following 0.6% PhAc treatment (blocks

7-12). n = 7 for each group. Data are presented as mean ± SEM. Individual data points

are overlaid.

Figure 4. Pharmacological blockade of enhanced memory retrieval by LC activation.

(**A**) Taste reactivity test in wild-type mice that received intra-amygdala infusion of

PRAZ (0.1 or 0.5 µg/site) and PROP (0.4 or 2.0 µg/site). n = 7-10 for each mouse group.

*p < 0.05 vs PBS infusion (Tukey HSD test). (**B**) Taste reactivity test showing the

blockade of shortened response latency in LC-activated Tg mice by the intra-amygdala

infusion of PRAZ and POROP at the lower doses (0.1 and 0.4 µg/site, respectively). n =

8 or 9 for each group in Tg mice. n = 7 for each non-Tg group. *p < 0.05, **p < 0.01 vs

PBS in Tg mice (Tukey HSD test). Data are presented as mean ± SEM. Individual data

1   points are overlaid.

Figure 5. Pharmacological inhibition of LC neurons impairs memory retrieval. (**A**)

Taste reactivity test showing the lengthened latency of rejection response in wild-type

mice by injection of an α_2-adrenergic receptor agonist CLO (10 and 25 ng/site) into the

LC. n = 7-8 for each mouse group. **p < 0.01, ***p < 0.001 vs the PBS-treated mice

(Tukey HSD test). (**B**) Restoration of delayed rejection response in the CLO-injected

mice (10 ng/site) by intra-amygdala infusion of adrenergic receptor agonists MET (0.5

μg/site) and ISO (1.25 μg/site). n = 8 for the MET and ISO-treated groups, n = 7 for

PBS-treated group. ***p < 0.001 vs the PBS-treated mice (Tukey HSD test). Data are

1   presented as mean ± SEM. Individual data points are overlaid.

1 **Figure supplements**

4 **Figure 1—figure supplement 1.** Histological analysis of transgene expression and

5 electrophysiological analysis in cultured cells. (**A**) Expression of transgene in

6 catecholamine-containing cell groups in TH-EGFP-IR84a/IR8a mice. Sections through

the olfactory bulb (A16), ventral midbrain (A10 and A9), and brain stem (A2/C2) of Tg

and non-Tg mice were prepared and stained by GFP immunohistochemistry. Transgene

expression was observed in many cells in the A16, A10, and A9 cell groups (dopamine

neurons) and in a few cells in the A2/C2 cell groups (NE/epinephrine neurons) of the Tg

mice. (**B**) In situ hybridization showing expression of IR84a or IR8a mRNAs in Tg

mice. Microscopic images of LC sections obtained from *in situ* hybridization with the

antisense probe for IR84a or IR8a. Scale bars: 200 μm (A): 400 μm (B). (**C**) Expression

of IR84a/IR8a complex in HEK293T cells transduced by a lentiviral vector encoding

transgene. Immunohistochemistry for EGFP (green) and HA tag (magenta) detected

expression of the 2 receptor subunits. Scale bar: 50 μm. (**D**) Ligand-induced inward

current of GFP-positive cells expressing the receptor complex. Bar graph showing the

current amplitude indicates a significant increase of the amplitude in GFP-positive cells

over that of GFP-negative control cells. The mean amplitudes of GFP-positive and

GFP-negative cells were 35.77 ± 7.91 pA (n = 11) and 11.14 ± 2.19 pA (n = 14),

respectively (Mann-Whitney's U = 28.00, p = 0.0073). Inset shows mean current traces

of the PhAc-induced inward current waveform. Solid and dotted lines indicate the

waveform of GFP-positive and negative cells, respectively. (**E**) Ligand dose responses

of the GFP-positive (n = 12) and GFP-negative (n = 8) cells. The amplitudes of the

ligand-induced currents were normalized in each cell to the amplitude at 0.01% PhAc.

PhAc-induced current responses were specific to GFP-positive cells and displayed dose

dependency (two-way mixed-design ANOVA, group effect: $F_{(1, 18)} = 8.457$, $p = 0.0094$,

dose effect: $F_{(3, 54)} = 4.396$, $p = 0.0077$, interaction: $F_{(3, 54)} = 8.509$, $p = 0.0001$,

simple-main effect of dose was significant for GFP-positive cells, $F_{(3, 54)} = 12.10$, $p <$

0.0001, but not for GFP-negative cells, $F_{(3, 54)} = 0.809$, $p = 0.4942$). The responses of

GFP-positive cells at 0.05% and 0.1% PhAc were significantly higher than those of

GFP-negative cells (simple-main effect tests of group, $F_{(1, 72)} = 7.863$, $^{**}p = 0.0065$, $F_{(1,}$

$_{72)} = 25.09$, $^{***}p < 0.0001$, respectively).

2 **Figure 2—figure supplement 1.** Microdialysis analysis of NE release and

3 morphological analysis of LC neurons after PhAc stimulation. (**A**) Microdialysis of NE

4 release in response to LC injection with lower doses of PhAc. PhAc solution (0.1%) or

PBS was injected into the LC of the Tg mice, and dialysis samples were collected from

the ACC. NE levels are expressed as a percentage of each animal's average baseline

levels. LC injection of 0.1% PhAc did not cause a significant increase in NE release in

the ACC (n = 3 for each group, two-way ANOVA, drug effect: $F_{(1, 4)} = 1.508$, p = 0.2868,

fraction effect: $F_{(6, 24)} = 1.481$, p = 0.2268, interaction: $F_{(6, 24)} = 1.747$, p = 0.1531). (**B**)

Placement sites of injection needles into the LC and dialysis probes into the ACC. (**C**)

Diagram for the microdialysis to monitor NE release from the amygdala (AMY) after

LC stimulation. PhAc solution (0.6%) or PBS was injected into the LC of the Tg mice,

and dialysis samples were collected from the amygdala. (**D**) Changes in extracellular

NE levels after PhAc injection in the Tg mice. NE levels are expressed as a percentage

of each animal's average baseline levels. Injection of 0.6% PhAc into the LC induced a

marked and sustained increase in the extracellular NE level in the Tg mice (n = 5 or 6

for each group, two-way ANOVA, drug effect: $F_{(1, 9)} = 7.008$, p = 0.0266, fraction effect:

$F_{(6, 54)} = 3.420$, p = 0.0062, interaction: $F_{(6, 54)} = 2.485$, p = 0.0340). In the PhAc group,

the NE level at a 30-min fractions was significantly elevated to approximately 155% of

the baseline level for PhAc injection ($F_{(1, 63)} = 9.409$, p = 0.0032 vs PBS group), and the

increases continued at 120-130% of baseline level during the subsequent fractions (p =

0.0204, 0.0212, and 0.0188 vs PBS group, for 60, 90, and 120-min fractions,

respectively). $*p < 0.05$, $**p < 0.01$ vs PBS (Holm-Bonferroni test). (**E**) Placement sites

of injection needles into the LC and dialysis probes into the amygdala. (**G**) Morphology

of LC neurons in the Tg mice after PhAc stimulation stained by TH/NET. Sections

through the LC were prepared from the Tg mice used for microdialysis analysis 7 days

after unilateral treatment with PBS or PhAc (0.4/0.6%) and stained for TH and NET

immunohistochemistry. LC cells in the PhAc-injected side appear to be normally

localized. (**H**) Cell counts for TH and NET-immunopositive cells. The ratio of the

number of cells stained for TH or NET in the treated side relative to the intact side was

calculated. There was no significant difference in the relative ratios of cell number

among the treated groups (n = 3 for each group, one-way ANOVA, $F_{(2, 6)} = 1.085$, p =

0.3961 for TH and $F_{(2, 6)} = 1.426$, p = 0.3115 for NET). (**I**) Staining of LC sections with

cresyl violet, showing no cell damage against LC neurons in the PhAc-treated side. (**J**)

Staining for cell death markers. Ibotenic acid (IBO, 1 mg/ml) or PhAc (0.6%) was

injected into the LC (0.2 µl/site) of the Tg mice. IBO was used as positive control to

detect cell death signals. LC sections were stained with terminal deoxynucleotidyl

transferase-mediated dUTP-biotin nick end labeling (TUNEL) or immunostaining for

activated caspase-3. The LC areas in the upper images were 4-fold magnified in the

lower images. The number of signals in the PhAc-treated side was profoundly lower

than in the IBO-treated side, confirming the lack of cytotoxicity of PhAc treatment

against LC cells expressing the IRs. Arrowheads indicate the injection sites into the LC.

Scale bar: 1 mm.

Figure 2—figure supplement 2. Placement sites of recording electrodes for *in vivo*

electrophysiology and injection needles and dialysis probes for microdialysis analysis.

(**A**) Sites of the recording electrodes in the LC for pneumonic injection of PhAc, related

to Figures 2B-D. (**B**) Sites of injection needles into the LC and for dialysis probes into

the ACC, related to Figure 2F. (**C**) Sites of the electrodes before and after systemic

1   administration of MPhAc or vehicle, related to Figure 2H. (**D**) Sites of dialysis probes

2   after systemic administration of MPhAc or vehicle, related to Figure 2I. The recording

3   sites were marked by pontamine sky blue, and after the experiments the brain sections

4   were prepared and stained by cresyl violet. Scale bars: 1 mm.

Figure 3—figure supplement 1. Quantification of aversive responses in the taste

reactivity Test. (**A**) Time course of aversive response number. Mice were given

intra-LC microinjection of PBS, 0.4% or 0.6% PhAc, and the taste reactivity test was

conducted. Behaviour was recorded using a digital video camera, and rejection

responses (including gaping, chin rubbing, forelimb flailing, paw wiping, and CS

dropping) during the 10-min test period were counted. The behavioral data used in

Figure 3C was analysed. The number of the responses at a 10-s bin were plotted. Insets

show the response number during the early period (< 100 s). (**B**) Total number of

aversive responses during the 10-min test. The number was not significantly different

among the three treatment groups in the Tg or non-Tg mice (one-way ANOVA; n = 8-9,

$F_{(2, 23)} = 0.969$, $p = 0.3945$ for Tg mice; n = 8-11, $F_{(2, 24)} = 0.033$, $p = 0.9677$ for non-Tg

mice). The aversive responses in the Tg mice were observed in the earlier bins in the

0.4% or 0.6% PhAc-injected group compared to the PBS-injected group, although these

changes were not seen in the non-Tg mice. The data support the shortening of latency

for the initiation of rejection behaviours after 0.4% or 0.6% PhAc treatment in the Tg

mice. The similarity of total number of aversive responses during the test period

suggests that PhAc treatment before the test does not alter the storage of taste memory

in Tg mice.

Figure 3—figure supplement 2. Placement sites of injection needles for behavioral

analysis of mice after LC microinjection. (**A**) Sites for the taste reactivity test, related to

Figure 3C. (**B**) Sites for the taste sensitivity test, related to Figure 3D. (**C**) Sites for the

taste reactivity test of unconditioned mice infused with 0.5 M sucrose, related to Figure

1   3E. (**D**) Sites for the taste reactivity test of unconditioned mice infused with 0.2 mM

2   quinine, related to Figure 3F. (**E**) Sites for the locomotor activity test, related to Figure

3   3G. After the behavioral tests, brain sections were prepared and stained by cresyl violet.

4   Scale bars: 1 mm.

Figure 4—figure supplement 1. Placement sites of the needles for pharmacological

blocking experiments against ligand-induced LC activation. (**A**) Sites for the taste

reactivity test in mice that received the treatment of adrenergic receptor antagonists into

1   the amygdala (AMY), related to Figure 4A. (**B**) Sites for the reactivity test after the

2   intra-amygdala treatment followed by LC stimulation, related to Figure 4B. After the

3   behavioral tests, brain sections were prepared and stained by cresyl violet. Scale bars: 1

4   mm.

Figure 5—figure supplement 1. Placement sites of the needles for behavioral tests of

mice that received LC pharmacological inhibition. (**A**) Sites for the taste reactivity test

after LC injection of CLO, related to Figure 5A. (**B**) Sites for the reactivity test after the

LC injection followed by the intra-amygdala treatment of adrenergic receptor agonists,

related to Figure 5B. After the behavioral tests, brain sections were prepared and stained

by cresyl violet. Scale bars: 1 mm.